

Antithrombotic Therapy for Venous Thromboembolic Disease

Thomas M. Hyers, MD, FCCP, Chair; Giancarlo Agnelli, MD; Russell D. Hull, MBBS, MSc, FCCP; Timothy A. Morris, MD, FCCP; Michel Samama, MD; Victor Tapson, MD, FCCP; and John G. Weg, MD, FCCP

Abbreviations: APTT = activated partial thromboplastin time; DVT = deep venous thrombosis; HIT = heparin-induced thrombocytopenia; INR = international normalized ratio; IPG = impedance plethysmography; LMW = low molecular weight; PE = pulmonary embolism; PTE = pulmonary thromboendarterectomy; TCT = thrombin clotting time; tPA = tissue plasminogen activator (alteplase); VTE = venous thromboembolism

(CHEST 2001; 119:176S-193S)

Stasis of blood, abnormalities of the vessel wall, and changes in the soluble and formed elements of the blood are the major contributors to thrombosis. All of these alterations can contribute to venous thrombosis, depending on the specific risk factors that are present in a given patient.

Antithrombotic regimens modify one or more of these abnormalities. These regimens include drugs that inhibit blood coagulation, such as the various heparins and heparinoids; warfarin; direct thrombin inhibitors; drugs that inhibit platelet function, such as aspirin and dextran; and techniques that counteract venous stasis, such as compression stockings and pneumatic compression devices. In this broad sense, thrombolytic agents are also antithrombotic (Table 1). This section will describe the effectiveness of antithrombotic agents in the treatment of venous thromboembolism (VTE), a disease that encompasses both deep venous thrombosis (DVT) and pulmonary embolism (PE). Several of these agents are also useful for the primary prevention of VTE, and this application of antithrombotic therapy is reviewed in the preceding chapter.

All antithrombotic therapy with either anticoagulants or platelet-active drugs is prophylactic, since these agents interrupt progression of the thrombotic process; but unlike thrombolytic agents, they do not as a rule actively resolve it. Unfractionated heparin, low-molecular-weight (LMW) heparin, thrombolytic agents, and warfarin are used to treat venous thromboembolic disease.

1. TREATMENT OF VTE

1.1. Effective Regimens

Treatment regimens for DVT and PE are similar because the two conditions are manifestations of the same disease process. When patients with VTE are carefully studied, the majority of those with proximal DVT also have PE (symptomatic or asymptomatic) and *vice versa*. Fur-

thermore, clinical trials in patients with DVT alone have validated treatment regimens that are similar to regimens used in patients with both DVT and PE and in patients known to have only PE. None of these studies established the superiority of a treatment regimen for patients with PE in stable condition that was substantially different than regimens for patients with DVT. Patients with VTE who receive adequate anticoagulation generally do not die of recurrent disease. However, it should be noted that patients who are treated for PE are almost four times more likely (1.5% vs 0.4%) to die of recurrent VTE in the next year than are patients who are treated for DVT.¹ The major exception to the statement that the two conditions are treated similarly is that patients with symptomatic proximal DVT may benefit from fitted compression stockings for at least 3 months to reduce the incidence of the postthrombotic syndrome.²

Heparin: Heparin, an acidic glycosaminoglycan, is a time-honored and relatively effective antithrombotic agent, but it requires careful monitoring and dose adjustment when used to treat active disease. Clinical preparations vary over a molecular weight range of 5,000 to 30,000 d, with a mean molecular weight of approximately 15,000 d. The drug acts by catalyzing the effect of a plasma inhibitor, antithrombin III, so that the inhibitor more efficiently combines with and inactivates a number of serine proteinases, notably thrombin (factor IIa), factor Xa, and factor IXa. Heparin also acts to inhibit activation of factors V and VIII by thrombin.^{3,4} Neither hepatic nor renal disease seem to interfere notably with the clearance of the drug at therapeutic concentrations.⁵ Heparin is currently obtained from the gut mucosa of animals and is available as a sodium or calcium salt.

The unit of heparin is measured in animals using a biological assay. Unitage may vary as much as 50% on a weight basis; consequently, heparin is properly prescribed by units, not weight.

Heparin has proved effective in the treatment of PE and DVT.⁶ The first and only trial that incorporated an untreated group with PE was completed before the advent of perfusion lung scanning and pulmonary angiography and has several other flaws. The much higher mortality (25%) in the untreated patients, combined with a demonstration of autopsy-verified PE as the cause of death, is persuasive. Subsequent studies^{7,8} have attested to the reduced mortality rate when heparin was used to treat VTE disease, and to the high mortality when patients with PE did not receive anticoagulant therapy.⁹ Recent randomized clinical trials¹⁰⁻¹⁶ have confirmed the efficacy of continuous IV heparin in the treatment of DVT. Other trials indicate that subcutaneous heparin is adequate initial therapy for DVT, provided that activated partial thromboplastin time (APTT) is prolonged into the therapeutic range or that adequate doses are used.¹⁷⁻¹⁹

Clinical trials have also shown the efficacy of heparin and warfarin in treating symptomatic calf vein thrombosis.^{20,21} Venous thrombosis that remains confined to the deep calf veins appears to be associated with a low risk of clinically important PE. In patients with asymptomatic calf vein DVT, serial testing with impedance plethysmography

Correspondence to: Thomas M. Hyers, MD, FCCP, Occupational Medicine and Pulmonary Diseases, 533 Couch Ave, Suite 140, St. Louis, MO 63122

Table 1—Antithrombotic Agents in VTE*

Agents	Mechanism of Action*	Onset of Action	Application	Usual Route of Administration	Contraindications
Heparin	With ATIII, prevents thrombin activity (anti-IIa) and to a lesser extent thrombin generation (anti-Xa)	Immediate	Prevention and treatment of VTE	IV or subcutaneous	Severe active bleeding; documented hypersensitivity; HIT
LMW heparins and heparinoids	With ATIII, inhibits thrombin generation by an effect on Xa, to a lesser extent on IIa	Immediate	Prevention and treatment of VTE	Subcutaneous	Severe active bleeding; documented hypersensitivity; HIT
Hirudin and direct thrombin inhibitors	Inhibits thrombin activity directly	Immediate	Prevention and treatment of VTE; treatment of HIT	IV	Severe active bleeding
Warfarin	Inhibits proper synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X)	4 to 5 d	Long-term treatment of VTE; prevention of VTE	Oral	Severe active bleeding; pregnancy; documented hypersensitivity
Streptokinase	Activates plasminogen, dissolves fibrin; degrades fibrinogen and several other plasma proteins	Immediate	Treatment of severe or life-threatening PE or DVT	IV	Active bleeding; recent surgery; stroke; or severe trauma; any hemorrhagic disease; recent streptococcal infection or treatment with streptokinase; documented hypersensitivity
Urokinase	Activates plasminogen, dissolves fibrin; degrades fibrinogen and several other plasma proteins	Immediate	Treatment of severe or life-threatening PE or DVT	IV	Active bleeding; recent surgery; severe trauma; any hemorrhagic disease
Alteplase	Activates plasminogen bound to fibrin; dissolves fibrin	Immediate	Treatment of severe or life-threatening PE or DVT	IV	Active bleeding; intracranial pathologic condition; recent surgery; severe trauma; any hemorrhagic disease
Retepase	Activates plasminogen bound to fibrin; dissolves fibrin	Immediate	Treatment of severe or life-threatening PE or DVT	IV	Active bleeding; intracranial pathologic condition; recent surgery; severe trauma; any hemorrhagic disease

*ATIII = antithrombin III

(IPC) or duplex ultrasound for 10 to 14 days appears to be effective for identifying patients with extending calf DVT; normal findings by serial IPC or ultrasound are associated with a low risk of clinically important PE (<1%) or recurrent venous thrombosis (2%). Patients with extending calf vein DVT, although asymptomatic, should probably be treated. Most patients with symptomatic calf vein thrombosis should receive anticoagulant therapy. An alternate approach is to follow up the patient with serial IPC or ultrasound to separate the 20% of patients who develop proximal extension (and require treatment) from the remaining 80% of patients who do not, in whom the risks of anticoagulant therapy may outweigh the benefits (eg, in patients at high risk of bleeding).²⁰ In contrast, superficial thrombophlebitis in the absence of DVT is generally treated effectively with nonsteroidal anti-inflammatory agents. However, it is necessary to perform duplex ultrasonography to be certain that DVT does not exist concurrently with superficial thrombophlebitis.²²

Heparin Dose and Bleeding: Plasma levels during administration of heparin are not easily predictable,^{5,23,24} and more specific assays for the drug have not been widely applied.²⁵ The lack of a clear relationship between heparin dose and bleeding probably results from the variable interference of heparin with platelet and endothelial cell function in patients.²⁶⁻²⁸ Please see the chapter on "Heparin and Low-Molecular-Weight Heparin: Mechanisms of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety" for details on the complex interaction of heparin dose, anticoagulation intensity, and bleeding.

Relationship Between Risk of Bleeding and Method of Administering Heparin: Six randomized studies²⁹⁻³⁴ compared the bleeding and thromboembolic recurrence rates when heparin was administered by intermittent IV injection or by continuous IV infusion. Two studies^{29,30} reported that continuous heparin infusion was associated

with a lower frequency of bleeding (1% and 0% compared with 9% and 33%), and the third study⁹¹ reported the trend toward reduced bleeding with continuous heparin, 5% compared with 10%. In the fourth study,⁹² there was a trend in the other direction. The other two studies^{93,94} were too small to draw clear conclusions about recurrence rates. Patients receiving continuous-infusion heparin, however, also received a lower dose of heparin. Therefore, it is uncertain whether the difference noted in the rates of bleeding between patients randomized to continuous IV infusion or intermittent IV injection is related to the method of heparin administered or to the difference in the total dose of heparin given to the two groups.

Only one randomized trial⁹⁰ evaluated the benefit of monitoring heparin therapy. In this study, patients received intermittent heparin injections, either with or without laboratory control using the APTT. There was no significant difference detected in the frequency of bleeding between the two groups (8% vs 10%), suggesting that when heparin is administered by intermittent injection, monitoring the response may not reduce the risk of bleeding.

Relationship Between Heparin Levels and Thrombus Inhibition:

It is generally accepted that a minimum level of heparin anticoagulation must be maintained to achieve an effective antithrombotic state^{10,11,34-37} and that inadequate anticoagulant therapy results in unacceptably higher rates of recurrent thromboembolism. Animal experiments support the concept that a plasma level of heparin between 0.2 IU/mL and 0.4 IU/mL (measured by protamine sulfate titration) is necessary to interrupt an ongoing thrombotic process.³⁸⁻⁴¹ The most widely used test for monitoring heparin therapy is the APTT, which is a global coagulation test and does not directly reflect plasma heparin levels.^{33,42,43} Inadequate initial heparin therapy seems to increase the long-term recurrence rate despite adequate long-term treatment.⁴⁴ A retrospective analysis published 3 decades ago suggested that recurrent VTE is infrequent if continuous IV heparin is administered in doses adjusted to prolong the APTT > 1.5 times the control value.³⁸ An analysis of a randomized, prospective trial¹⁰ comparing IV and subcutaneous heparin administration in patients with proximal vein thrombosis demonstrated that failure to achieve an adequate anticoagulant response (APTT > 1.5 times control) is associated with a high risk (30 to 25%) of recurrent VTE. In that study,¹⁰ the control APTT value was defined as the mean APTT obtained from pooled plasma of normal volunteers. An analysis⁴⁵ of three consecutive double-blind trials supports this observation. In general, an APTT > 1.5 times control or mean normal corresponded to a blood heparin level of 0.2 IU/mL in these studies. However, other analyses⁴⁶⁻⁴⁹ of clinical trial results suggest that the risk of recurrence depends also on the heparin dose itself. Clinical recurrence is unusual as long as heparin is infused IV in a dose of at least 1,250 U/h.⁴⁵

The APTT does not always correlate reliably with plasma heparin levels or with antithrombotic activity. The APTT can be shortened by increased levels of various plasma proteins and clotting factors such as factor VIII,

which is an acute-phase reactant, and the anticoagulant effect of heparin can be suppressed by variable concentrations of heparin-binding proteins in plasma.⁴⁹ Moreover, the APTT is dependent on the coagulation timer and reagents used to perform the test.⁵⁰ Consequently, clinicians are often perplexed by patients with acute thrombosis who require large amounts of heparin (> 40,000 U/d) but do not have "therapeutic" clotting times and occasionally by patients who seem to have therapeutic times and yet suffer recurrent thrombotic events.

LMW heparins should obviate some of these problems because these products have a more predictable dose-response relationship when administered on the basis of body weight. These agents can be used to treat many patients with acute DVT without the need for subsequent monitoring or dose adjustment. When one considers the global costs of treating VTE, LMW heparins are cost-effective.⁵¹⁻⁵⁵ However, LMW heparins have only recently come into use in North America, largely for treatment of acute DVT. Given the current period of transition from one treatment method to another, it is important to optimize management protocols for unfractionated heparin as well as to develop new protocols for LMW heparin.

Both animal and human studies have shown that a plasma heparin level in the range of 0.2 to 0.4 IU/mL (protamine sulfate titration) inhibits thrombus propagation.^{38-41,56} This hypothesis was tested in a controlled clinical trial⁵⁶ in which patients with acute VTE who required large doses of heparin (> 35,000 U/d) were randomized to either continued APTT monitoring or direct monitoring of blood heparin levels. Subsequent dosage adjustments were made according to the monitoring test employed. Patients whose heparin level was monitored directly required less heparin than did patients receiving APTT monitoring. Outcome differences between the two groups were statistically insignificant, although trends favored decreased recurrent thromboembolism and bleeding in the group monitored by plasma heparin levels. Measuring plasma heparin levels rather than the APTT is probably more appropriate to monitor and dose-adjust heparin in the treatment of acute thrombosis, but this approach should be validated in larger studies.

Unfortunately, many hospital laboratories are not prepared to monitor heparin levels directly and expeditiously report the results, although automated assays for heparin levels show promise.⁵⁷ A practical compromise is prospective determination in each laboratory of the therapeutic range of the APTT in seconds that corresponds to plasma heparin levels from 0.2 to 0.4 IU/mL by protamine sulfate titration or 0.3 to 0.6 IU/mL by an amidolytic assay. This correlation should preferably be done *ex vivo* using plasma specimens from at least 30 to 40 patients receiving heparin therapy. If it can be shown that the therapeutic range established *ex vivo* is similar to that established *in vitro* by using plasma specimens spiked with known concentrations of heparin, the latter method, which is more practical and less expensive, may be used. If the conditions of the APTT change, eg, use of a new APTT reagent or reagent batch, new coagulation timer, or heparin preparation, then the therapeutic range for heparin must be reestablished.

Given the continued lack of an international reference APTT reagent preparation that would allow development of a normalized ratio system for heparin analogous to the international normalized ratio (INR) for warfarin, establishing the therapeutic range in each laboratory as described above is recommended as a way to standardize heparin therapy at this time.

An alternative to the APTT is the thrombin clotting time (TCT). This assay is easily performed, has a rapid turnaround time, and is linear in seconds between plasma heparin levels of 0.2 to 0.6 U, which includes the therapeutic range of heparin.⁶⁸ The TCT has greater specificity than the APTT in predicting heparin levels, is more reproducible, and is not affected as much by warfarin.^{69–71} The TCT may be shortened when antithrombin levels are low,⁶⁸ and fibrinogen levels < 100 mg/dL may prolong the test by several seconds. As with the APTT, plasma heparin levels should first be correlated with the TCT *ex vivo* before the test is used clinically.

Heparin is cleared rapidly from the plasma, with an average half-life of < 60 min when given in therapeutic doses.^{53,64} Audits of heparin therapy indicate that the current clinical practice of intuitive ordering of heparin often results in inadequate anticoagulation, probably because of fear of bleeding.^{65–67} The importance of exceeding the lower limit of the therapeutic range has been strongly supported by findings of prospective clinical trials. Indeed, firm evidence indicates that failure to exceed the lower limit is associated with unacceptably high rates of recurrent VTE.^{44,45,53}

In the first few days of heparin therapy, a weak association exists between supratherapeutic APTT responses and bleeding, which is in direct contrast to the clear association between subtherapeutic APTT responses and recurrent VTE.^{10,11,44,45} Several nomograms have been published^{66–68} to aid the clinician in reaching and maintaining the therapeutic range with heparin anticoagulation. All of these approaches are based on frequent monitoring of the APTT in the first few days of therapy and rapid response to subtherapeutic or supratherapeutic values for the APTT. In this regard, when the APTT is too low, one can raise the blood level of heparin quicker by giving another bolus and increasing the constant infusion rate simultaneously. Conversely, when the APTT is too prolonged, the heparin infusion can be discontinued for a

short time not to exceed 1 h. Table 2 gives a weight-based nomogram⁶⁷ that has been widely employed for dosing and adjusting therapy.

Perhaps the most common mistake with heparin dosing is the choice of an inadequate maintenance dose. Whether the heparin dose is calculated on a body weight basis or not, the average daily maintenance dose is generally > 30,000 IU (18 U × 70 kg × 24 h = 30,240 IU).^{10,68,70} When unfractionated heparin is given subcutaneously as an initial anticoagulating dose, therapy should begin with a small IV loading dose (3,000 to 5,000 U) followed by 17,500 U (or 250 IU/kg) subcutaneously q12h.¹⁸ The dose should then be adjusted to give an APTT that corresponds to a plasma heparin level of 0.2 IU/mL within 1 h of the next scheduled subcutaneous dose. Heparin requirements are usually greatest in the first few days after the acute thromboembolic event^{63,72,74}; consequently, therapy should be monitored most closely then. After the first few days, the monitoring test can usually be obtained daily.

Heparin-Induced Thrombocytopenia: Heparin can induce thrombocytopenia,^{69–75} but recent studies^{12–15} indicate that the frequency of heparin-induced thrombocytopenia (HIT) is < 1% when either unfractionated heparin or LMW heparin is given for no more than 5 to 7 days. Because of this finding, a platelet count should be checked between day 3 and day 5 of therapy. If heparin is administered for a longer period, another platelet count should be checked between day 7 and day 10 and another at day 14. The syndrome of HIT is unusual after 14 days of heparin therapy, although HIT complicated by thrombosis can sometimes develop after heparin therapy has been stopped. When the platelet count falls precipitously or in a sustained fashion, heparin therapy should be stopped. When the platelet count falls to < 100,000/μL, heparin therapy should be stopped. A marked fall in platelet count can signal antibody-mediated injury to platelets and endothelium. This syndrome may be associated with arterial thromboembolism and extension or recurrence of existing VTE.⁷⁶ If heparin therapy must be discontinued when the risk for recurrent embolism is great, many clinicians believe an inferior vena caval filter should be placed.

Table 2—Body Weight-Based Dosing of IV Heparin*

APTT, s†	Dose Change, U/kg/h	Additional Action	Next APTT, h
< 35 (<1.2 × mean normal)	+ 4	Rebolus with 80 IU/kg	6
35–45 (1.2–1.5 × mean normal)	+ 2	Rebolus with 40 IU/kg	6
46–70† (1.5–2.3 × mean normal)	0	0	6‡
71–90 (2.3–3.0 × mean normal)	– 2	0	6
> 90 (> 3.0 × mean normal)	– 3	Stop infusion 1 h	6

*Initial dosing: loading, 80 IU/kg; maintenance infusion; 18 IU/kg/h (APTT in 6 h).

†The therapeutic range in seconds should correspond to a plasma heparin level of 0.2 to 0.4 IU/mL by protamine sulfate or 0.3 to 0.6 IU/mL by amidolytic assay. When APTT is checked at 6 h or longer, steady-state kinetics can be assumed.

‡Heparin, 25,000 IU in 250 μL D.W. Infuse at rate dictated by body weight through an infusion apparatus calibrated for low flow rates.

§During the first 24 h, repeat APTT every 6 h. Thereafter, monitor APTT once every morning unless it is outside the therapeutic range.

Recombinant hirudin and danaparoid have become available for use in HIT. Recombinant hirudin (lepirudin) has been specifically approved for HIT accompanied by thrombosis. In this setting, lepirudin should be used for temporary anticoagulation and warfarin therapy delayed until the platelet count has risen to $>100,000/\mu\text{L}$.⁷⁷ Details for treatment regimens of these new drugs are given in the chapter on mechanisms of action of heparin and LMW heparins.

Heparin use commonly leads to mild reductions in the level of circulating antithrombin III, and rarely, has been reported to induce disseminated thrombosis.⁷⁸ Long-term high-dose (4 months at 15,000 IU/d) heparin administration can lead to severe osteopenia.^{79–83} In the rare patient with hypoadosteronism, heparin may induce hyperkalemia.⁸⁴ Heparin causes mild asymptomatic elevation of liver enzyme levels in some patients between day 5 and day 10 of treatment.^{85–88} These elevations either return to normal during treatment or following treatment without obvious untoward effect.

If a treatment dose of heparin is contraindicated for a patient with acute VTE, as it would be for someone with an actively bleeding CNS lesion, the acceptable alternative is insertion of a vena caval filter. Substitution of low-dose, prophylactic heparin or aspirin for full-dose heparin in this setting is ineffective.

1.2. Initial Anticoagulation With Heparin

Heparin is usually administered IV for 5 to 7 days in recovering patients. Unfortunately, such a short period of anticoagulation does not seem to interrupt completely the thrombotic process in many patients with proximal DVT. In one study, 10 to 14 days of conventional IV heparin therapy followed by low-dose subcutaneous heparin therapy did not adequately prevent recurrent VTE.⁸⁹ Consequently, most clinicians accompany the initial course of heparin with warfarin or another coumarin derivative for longer-term oral anticoagulation. The alternative is to give LMW heparin in a treatment dose^{12–16,60,91} or give heparin in a larger subcutaneous dose that maintains the anticoagulated state for the full duration of treatment.^{17,18,90,92}

The optimal duration of initial IV heparin therapy in patients with VTE appears to be 5 to 7 days, although therapy is sometimes prolonged in those with extensive

disease (Table 3). Multiple randomized clinical trials in patients with proximal vein thrombosis indicate that when IV heparin is administered for 5 to 10 days and followed by adequate long-term anticoagulant therapy, the frequency of recurrent VTE is approximately 5%. The currently accepted approach is to begin heparin and oral anticoagulant therapy together at the time of diagnosis and to discontinue the heparin therapy between the fourth and seventh day. This approach seems to be effective and avoids an additional 4 to 5 days of subsequent hospitalization in many patients, greatly reducing the cost of initial therapy. Several randomized trials in patients with VTE have shown that 5 to 7 days of initial heparin therapy coupled with early warfarin initiation and treatment for at least 3 months is effective and safe.^{12–16,60,70} It seems reasonable to recommend that heparin be given for 5 to 7 days and that warfarin be administered jointly with heparin for at least 4 to 5 days. Heparin therapy may then be discontinued when the prothrombin time yields an INR >2.0 (Table 3).

LMW Heparin: Although continuous IV unfractionated heparin therapy is usually effective and safe, the regimen nearly always requires hospitalization with frequent monitoring and dose adjustment. LMW heparin as initial treatment of proximal vein thrombosis, which can be given without dose adjustment or laboratory monitoring, has lowered costs by allowing outpatient therapy in patients with DVT.^{12,13} This approach to therapy has recently been reviewed.⁹² Estimates of the number of hospital days that would be saved by outpatient administration of therapy average 5 to 6 days for each patient. Utilization of LMW heparin with a component of outpatient therapy could save approximately \$250 million annually in the United States alone.^{51–53,93} A recent publication⁹⁴ has given guidelines for selecting patients for outpatient therapy. Table 4 gives minimal requirements for outpatient treatment of VTE.

LMW fractions of heparin have a mean molecular weight of 4,000 to 5,000 d in contrast to unfractionated heparin, which has a mean molecular weight of 15,000 d.^{95,96} The excellent bioavailability of LMW heparin, together with a longer plasma half-life^{97–103} (as measured by anti-Xa activity) than unfractionated heparin, suggested that it would be possible to develop an effective regimen for initial treatment with LMW heparin using a once-

Table 3—Guidelines for Anticoagulation: Unfractionated Heparin*

Indication	Guidelines
VTE suspected	<ul style="list-style-type: none"> • Obtain baseline APTT, PT, CBC count • Check for contraindication to heparin therapy • Order imaging study, consider giving heparin 5,000 IU IV
VTE confirmed	<ul style="list-style-type: none"> • Bolus with heparin 80 IU/kg IV and start maintenance infusion at 18 U/kg (see Table 2) • Check APTT at 6 h to keep APTT in a range that corresponds to a therapeutic blood heparin level (see text and Table 2) • Check a platelet count between days 3 to 5 • Start warfarin therapy on day 1 at 5 mg and adjust subsequent daily dose according to INR • Stop heparin therapy after at least 4 to 5 d of combined therapy when INR is >2.0 • Anticoagulate with warfarin for at least 3 mo at an INR of 2.5; range, 2.0 to 3.0 (see Table 6)

*For subcutaneous treatment with unfractionated heparin, give 250 IU/kg subcutaneously q12h to obtain a therapeutic APTT at 6–8 h.

PT = prothrombin time.

twice-daily subcutaneous injection. The anticoagulant response (anti-Xa U/mL) observed with a given dose of LMW heparin was highly correlated with body weight,¹⁰² and LMW heparin is effective in most patients when given in weight-based doses (anti-Xa U/kg body weight) without subsequent laboratory monitoring or dose adjustment.¹²⁻¹⁶ All LMW heparins are cleared by the kidneys and caution should be exercised when the creatinine clearance is < 30 mL/min. The correct dose for massively obese persons has not been established, and laboratory monitoring (plasma anti-Xa activity) may be useful in such patients. Some authorities also recommend monitoring pregnant patients because the pharmacokinetics of LMW heparins appear to change during pregnancy, probably because of increased renal clearance of the drug.¹⁰⁴

Studies in animal models of venous thrombosis have shown that some LMW fractions have equal (or greater) antithrombotic efficacy but less hemorrhagic effects than unfractionated heparin.^{96,97,105-108} Whether this experimental observation applies clinically is uncertain,¹⁰⁵⁻¹⁰⁷ since studies¹²⁻¹⁶ have shown similar bleeding rates with unfractionated heparin and LMW heparin.¹

Multiple early randomized clinical trials^{105,106,109-122} with differing end points compared LMW heparin with unfractionated heparin for the initial treatment of patients with venous thrombosis. Five studies^{106,110,111,114,116} compared continuous IV LMW heparin with continuous IV unfractionated heparin, one trial¹¹³ compared subcutaneous LMW heparin with subcutaneous unfractionated heparin, and four studies^{115,117,123,124} compared subcutaneous LMW heparin with continuous IV unfractionated heparin. The results indicate that LMW heparin administered subcutaneously is as effective and safe as continuous IV heparin, but in the early studies,¹⁰⁹⁻¹²² conclusions of efficacy were largely based on venographic observations rather than clinical outcome.

LMW Heparin or Unfractionated Heparin? Several studies^{12-16,125-130} have evaluated long-term clinical outcome using LMW heparin. Most studies^{12-15,125-130} showed comparable outcomes when LMW heparin dosed subcutaneously without monitoring was compared with IV unfractionated heparin with monitoring and subsequent dose adjustment. One large study¹²⁴ showed lower rates of recurrence and bleeding when LMW heparin was compared to unfractionated heparin. Several meta-analyses^{131,132} have also suggested that LMW heparin results in fewer episodes of recurrence and bleeding than unfractionated heparin. A small survival benefit may accrue to patients with malignancy and VTE who receive LMW heparin.^{131,133}

Two studies^{12,13} have shown that selected patients with proximal venous thrombosis can be treated at home with LMW heparin and warfarin therapy initiated together. When treatment is given at home, cost savings and improved quality of life are realized. In addition, selected patients can be discharged from the hospital early with a component of LMW heparin treatment at home.¹²⁻¹⁶ While a few studies^{123,124} suggested fewer recurrent events and less bleeding with LMW heparin, most studies^{12-16,112-130} have not supported these find-

ings in the treatment of VTE. Thus, the major advantages of LMW heparin in treatment appear to be convenience of administration and cost savings associated with home therapy or early hospital discharge.¹³²

In summary, the LMW heparins used in these studies were at least equivalent to IV unfractionated heparin therapy. LMW heparin regimens offer the potential for treating selected patients with stable proximal DVT or PE in an outpatient setting and may offer particular benefit in those with malignancy. Not all patients with VTE are candidates for home treatment or early hospital discharge. The treating physician is best prepared to make these decisions (Table 4).

Accumulating evidence indicates that LMW heparin administered subcutaneously will largely replace IV unfractionated heparin therapy in the initial treatment of VTE. In most patients, subcutaneously administered LMW heparins do not require routine monitoring. Thrombocytopenia is uncommon enough that no more than one platelet count is recommended during a treatment period of 5 to 7 days. If therapy is prolonged > 7 days, subsequent platelet counts should be done.

Despite the care taken with meta-analysis, properties associated with one LMW heparin cannot always be extrapolated to a different LMW heparin, since treatment regimens differ somewhat for each drug. Table 5 gives recommendations for initiating treatment of DVT with LMW heparins that are approved for use in either the United States or Canada.

Treatment of VTE with LMW heparin has come of age. A large body of data for several of these products has been provided by well-designed clinical trials that featured clinically relevant end points. Estimates of treatment effect are available with acceptable confidence intervals. Treatment effects appear generalizable, *i.e.*, they apply to large populations of patients with VTE. Outpatient treatment of only a small minority of patients with VTE shifts overall costs of care in favor of LMW heparin. All of these findings argue strongly for use of LMW heparin in many patients with VTE.

Hirudin and Other Small Thrombin Inhibitors: Hirudin is the progenitor of a family of peptides that directly inhibit thrombin independent of an interaction with antithrombin. Because of this property, these peptides, particularly the smaller analogs, more effectively inhibit fibrin deposition in the interstices of a developing thrombus than does the larger heparin-antithrombin complex.¹³³ In experimental models of arterial and venous thrombosis, hirudin was more effective than heparin as an antithrombin.¹³⁴⁻¹³⁶ These drugs also appear promising in clinical prophylaxis and treatment.^{136,137} Recombinant hirudin (lepirudin) is available in the United States for treatment of HIT with thrombosis.¹³⁸ Argatroban, another direct thrombin inhibitor, has recently received US Food and Drug Administration approval in the United States.¹³⁹

Coumarin Derivatives: These drugs are chemical derivatives of 4-hydroxycoumarin. They are well absorbed in the gut and transported in plasma bound to albumin. The drugs are metabolized by the liver and excreted in a

hydroxylated form in the urine. In North America, the predominant coumarin derivative in clinical use is racemic sodium warfarin.

Coumarins act in the liver by inhibiting the synthesis of four vitamin K-dependent coagulant proteins, factors II, VII, IX, and X, and at least two vitamin K-dependent anticoagulant factors, proteins C and S. The synthesis of other vitamin K-dependent proteins is also impaired, although the significance of this inhibition is uncertain since the function of other vitamin K-dependent proteins is largely unknown. The major mechanism of action is inhibition of a specific posttranslational event in protein synthesis: the γ -carboxylation of multiple glutamic acid residues near the amino terminus of the polypeptide chain. The failure of γ -carboxylation of glutamic acid residues markedly interferes with the function of the proteins by preventing calcium binding^{140,141} and proper alignment of the activated factors on a phospholipid surface.¹⁴³ In the presence of coumarins, a number of analogous proteins are synthesized and released that not only are hypofunctional but also can interfere with normal coagulation reactions.^{143,144} For this reason, plasma from patients receiving coumarin cannot be compared directly with dilutions of normal plasma or with plasma from individuals who congenitally lack vitamin K-dependent coagulation factors.

Coumarins require several days to achieve their full effect because time is required for normal coagulation factors to be cleared from plasma. This lag period varies according to the plasma clearance rates of the K-dependent factors, being shortest for factor VII and longest for factor II. Accordingly, the one-stage prothrombin time might appear adequately prolonged 24 h after a large loading dose of a coumarin derivative because of the relatively short half-life of factor VII, but plasma levels of the other three factors would still be high.¹⁴⁵ Moreover, proteins C and S, which have anticoagulant and fibrinolytic effects, are also vitamin K dependent. Protein C has plasma clearance kinetics similar to factor VII.¹⁴⁶ Therefore, by reducing effective protein C levels, a large loading dose of a coumarin derivative might tip the hemostatic balance toward coagulation rather than anticoagulation in the first 24 to 48 h of therapy. Animal studies and anecdotal clinical experience support the need for a period of overlap of heparin and warfarin therapy when treating acute VTE.¹⁴⁷⁻¹⁴⁹ Early introduction of warfarin on day 1 or day 2 at a starting dose of 5 mg will usually keep the

total duration of heparin therapy at no more than 7 days.^{18-19,20,69,70,149,150} In this way, the incidence of HIT can also be minimized.

Monitoring Coumarin Therapy: Therapy is most commonly monitored with the one-stage prothrombin time.¹⁵¹ When monitoring coumarin therapy, it is important to recognize that the heparin can be easily removed from plasma samples before performing the prothrombin time.^{152,153} The clotting time is measured after mixing citrated plasma with calcium and a well-characterized tissue thromboplastin. Commercially available tissue thromboplastins vary in their sensitivity to the warfarin effect. Consequently, prothrombin times performed with different thromboplastins are not always directly comparable,¹⁵⁴ which has resulted in much confusion over the years as to the intensity of the anticoagulant effect required. This problem has been substantially alleviated with widespread adoption of the INR and use of thromboplastins with international sensitivity index values near 1.0. It also appears that using a 3.2% citrate tube filled to the full volume is important to help standardize the INR.¹⁵⁵ Another major difficulty with coumarin therapy is the number of factors that influence coumarin metabolism and action. A complete review of these factors is beyond the scope of this chapter. These interactions have been reviewed recently.¹⁵⁶ Ideally, a patient treated with warfarin should be receiving as few other drugs as possible, should use alcohol not at all or only moderately, and should be consuming a diet that contains a consistent amount of vitamin K.¹⁵⁷

Intensity of Coumarin Therapy: As with heparin, a threshold effect of warfarin seems necessary to achieve the antithrombotic state.^{36,37} Evidence from multiple studies over the last decade indicates that effective therapy in VTE is reflected by an INR of 2.0 to 3.0.^{18-19,20,69,70,158,159} These studies demonstrated that anticoagulation with warfarin to an INR of 2.0 to 3.0 results in fewer bleeding complications yet protects adequately against recurrent thromboembolism. In treating VTE or preventing it in higher-risk patients, the recommended therapeutic range for the prothrombin time is an INR of 2.0 to 3.0 with a target of 2.5.¹⁶⁰

1.2 Long-term Anticoagulation

The duration of anticoagulation for VTE must be tailored to the individual patient. In selected patients whose risk factors can be interrupted, eg, pharmacologic estrogen use or transient immobilization, < 3 months of therapy may be sufficient, although adequate clinical trials should be performed validating this brief a duration of therapy before such a recommendation is made.¹⁶¹⁻¹⁶⁴ Patients with slowly resolving risk factors, eg, prolonged immobilization, should be treated for at least 3 months. Patients with cancer, antithrombolytic syndrome, deficiency of antithrombin III, or recurrent VTE from any cause should be treated for longer periods. Patients with homozygous factor V Leiden or multiple thrombophilic states should probably be treated for longer periods.

Table 4—Minimal Elements for Early Discharge or Outpatient Therapy

Responsible physician must ensure the following:

- Patient in stable condition with normal vital signs
- Low bleeding risk
- Absence of severe renal insufficiency
- Practical system for administration of LMW heparin and warfarin with appropriate monitoring
- Practical system for surveillance and treatment of recurrent VTE and bleeding complications

Table 5—Guidelines for Anticoagulation With LMW Heparin

Indications	Guidelines
VTE suspected	<ul style="list-style-type: none"> • Obtain baseline APTT, PT, CBC • Check for contraindication to heparin therapy • Order imaging study, consider giving unfractionated heparin 5,000 U IV or LMW heparin
VTE confirmed	<ul style="list-style-type: none"> • Give LMW heparin (dalteparin*, enoxaparin†, nadroparin‡, tinzaparin§) • Start warfarin therapy on day 1 at 5 mg and adjust the subsequent daily dose according to INR • Check a platelet count between days 3 to 5 • Stop LMW heparin therapy after at least 4 to 5 d of combined therapy when INR is > 2.0 • Anticoagulate with warfarin for at least 3 months at an INR of 2.5, range of 2.0–3.0 (see Table 6)

*Dalteparin sodium 800 anti-Xa IU/kg/d subcutaneously. Single dose should not exceed 18,000 IU. (approved in Canada). PT = prothrombin time.

†Enoxaparin sodium 1 mg/kg q12h subcutaneously or enoxaparin sodium 1.5 mg/kg/d subcutaneously. Single daily dose should not exceed 180 mg (approved in both the United States and Canada).

‡Nadroparin calcium 86 anti-Xa IU/kg bid subcutaneously for 10 days (approved in Canada) or nadroparin calcium 171 anti-Xa IU/kg subcutaneously daily. Single dose should not exceed 17,100 IU.

§Tinzaparin sodium 175 anti-Xa IU/kg/d subcutaneously daily (approved in Canada and the United States).

Patients who are heterozygous for factor V Leiden should receive at least 3 months of treatment following a first event (Table 6).

In an early controlled trial that addressed duration, 2 weeks of adequate anticoagulation was not sufficient.⁸⁹ However, trials^{21,155–157} comparing shorter periods of therapy (3 to 6 months) with longer periods (> 6 months) always demonstrated lower recurrence rates with the longer periods of treatment, a benefit that accrued mostly to patients with idiopathic thrombosis. Thus, the strongest support for extended duration of treatment applies to those with idiopathic thrombosis, who should be treated with anticoagulant drugs for at least 6 months after a first episode. More studies are needed to identify specific patients who need long-term treatment. One trial in patients who had suffered two separate events showed reduced recurrence with prolonged anticoagulation (> 2 years).²¹ Benefit again occurred predominantly in patients with idiopathic venous thrombosis, but it was partially offset by increased bleeding associated with longer therapy.²¹ Table 6 offers recommendations for length of therapy based on underlying risk for recurrence. In this regard, one should remember that a very important risk factor for recurrent VTE is a prior event. Increasing age is also an important risk factor and should be considered when determining length of therapy. These recommendations are of grade C quality because to our knowledge, there have been no controlled trials of duration of therapy in most of the acquired or hereditary conditions listed in Table 6. A number of trials are in progress, and new information will be forthcoming. However, patients with any of these conditions are known to be at higher risk for recurrence than are those with reversible or time-limited risk factors, and it is reasonable, although unproved, to recommend longer periods of therapy.²¹

Complications: The major complication associated with warfarin use is hemorrhage.^{163,164} The risk of bleeding is related to prolongation of the INR. There is now abundant evidence that bleeding, but not efficacy, is reduced when the therapeutic range is reduced from an INR of 3.0 to 4.5

to an INR of 2.0 to 3.0. To minimize bleeding, investigators have sought to find the lowest effective level of anticoagulation, and current evidence strongly supports the concept that anticoagulation for VTE above an INR of 3.0 is generally unnecessary.^{185,189,194–197} One possible exception to this statement appears to be patients with the antiphospholipid antibody syndrome who may require a higher INR.^{148,177} Any vascular site in the body can bleed with coumarin therapy, but many observers have been impressed by the frequency with which localized organic lesions (tumors, ulcers, cerebral aneurysms) bleed following induction of anticoagulant therapy. If clinically indicated, the effects of warfarin effects can be corrected within 24 h by administration of vitamin K. Serious bleeding can be treated with fresh frozen plasma. Less serious bleeding associated with a modest elevation of the INR can generally be treated by withholding warfarin therapy or giving small doses (1 to 2 mg) of oral or subcutaneous vitamin K.¹⁷⁸

Much is made of the bleeding complications associated with heparin and warfarin, but it is important to remember the high mortality and morbidity rates associated with untreated and undertreated VTE.^{6–9}

Another complication associated with the coumarins is a vascular purpura that causes skin necrosis and occurs occasionally in the first weeks of therapy.^{179–181} This complication has been associated with protein C deficiency and malignancy.^{182–184} Coumarins cross the placenta and cause spontaneous abortion and specific embryo abnormalities if administered in the first trimester of pregnancy.^{185–186} Therefore, warfarin must not be administered during pregnancy, and all women of childbearing potential receiving warfarin must avoid becoming pregnant. The long-term therapy of choice in pregnant women is a treatment dose of LMW heparin or unfractionated heparin given subcutaneously in an adjusted dose to prolong the APTT to a range that corresponds to a plasma heparin level of 0.2 to 0.4 IU/mL for most of the dosing interval. Warfarin is administered routinely in the postpartum period, even to nursing mothers, since the drug metabolite excreted in breast milk is not an anticoagu-

lant.^{197,198} Patients who develop VTE during pregnancy should receive postpartum therapy with warfarin for at least 6 weeks.¹⁹⁹

Cost-Effectiveness of Anticoagulant Therapy: Cost-effective anticoagulant therapy should arrest thrombosis and prevent recurrent VTE, have a low incidence of bleeding and other complications, and be convenient and inexpensive to administer. An early cost-effectiveness analysis¹⁹⁰ ranked several anticoagulant regimens. These regimens all began with a 10- to 14-day course of IV heparin followed by various long-term regimens. In this analysis, warfarin therapy (INR 2.0 to 3.0) was most cost-effective for long-term anticoagulation in most patients with VTE. Adjusted-dose subcutaneous heparin or LMW heparin would be the long-term treatment of choice for pregnant patients and those with hypersensitivity to warfarin, or when laboratory facilities are inadequate to monitor warfarin therapy. In some settings, home monitoring of warfarin therapy might afford additional savings.

More recently, LMW heparin combined with early initiation of warfarin therapy promises to be the most cost-effective therapy because many patients can be treated without hospitalization or with very short inpatient stays.¹²⁻¹⁶ In many locales, this statement already applies to both inpatient and outpatient treatment.⁵¹⁻⁵⁵ Since the price of LMW heparins has begun to fall, it is expected that statements favoring cost-effectiveness of these drugs will become even more generalizable.

2. THROMBOLYTIC THERAPY

Thrombolytic agents dissolve thrombi by activating a zymogen, plasminogen, to the active agent, plasmin. Plasmin, when in proximity to a thrombus or a hemostatic plug, degrades fibrin to soluble peptides.¹⁹¹ Circulating plasmin also degrades soluble fibrinogen and, to some extent, several other plasma proteins. Streptokinase, urokinase, and tissue plasminogen activator (alteplase [tPA]) are the thrombolytic agents currently approved for clinical use in VTE.

Both streptokinase and urokinase have similar thrombolytic effects as judged by large clinical trials in PE.^{192,193} Using paired angiographic comparisons in each patient, resolution of thromboembolus, seen with 12 h or 24 h of urokinase therapy or 24 h of streptokinase therapy, was comparable at 24 h and was approximately three times that seen with heparin alone. Pulmonary vascular resistance was also reduced at 24 h by 35% compared with 4% in the heparin group. Whereas initial lung scan improvement was greater in the thrombolytic group at 1 day and 3 days, subsequent scan improvement was similar in the two groups. Twelve hours of urokinase therapy had equivalent thrombolytic efficacy to 24 h of streptokinase therapy, and these are the recommended infusion times for PE.¹⁹⁴ tPA has comparable thrombolytic capacity to urokinase and streptokinase and can be administered for shorter duration.¹⁹⁵

The use of thrombolytic therapy in the treatment of DVT and PE remains highly individualized. In treatment of DVT, early use of a thrombolytic agent such as strep-

Table 6—Duration of Therapy*

3 to 6 mo	<ul style="list-style-type: none"> First event with reversible† or time-limited risk factor (patient may have underlying Factor V Leiden or prothrombin 20210)
≥ 6 mo	<ul style="list-style-type: none"> Idiopathic VTE, first event
12 mo to lifetime	<ul style="list-style-type: none"> First event‡ with <ul style="list-style-type: none"> Cancer, until resolved Anticardiolipin antibody Antithrombin deficiency Recurrent event, idiopathic or with thrombophilia

*All recommendations are subject to modification by individual characteristics including patient preference, age, comorbidity, and likelihood of recurrence.

†Reversible or time-limited risk factors: surgery, trauma, immobilization, estrogen use.

‡Proper duration of therapy is unclear in first event with homozygous factor V Leiden, homocystinemia, deficiency of protein C or S, or multiple thrombophilias; and in recurrent events with reversible risk factors.

tokinase can decrease subsequent pain, swelling, loss of venous valves, and in some studies has reduced incidence of the postphlebotic syndrome.¹⁹⁶⁻²⁰⁰ However, this syndrome is notoriously slow and variable in its development, and conflicting findings^{201,202} mandate that further long-term controlled studies be performed. For PE, thrombolytic therapy followed by heparin clearly achieves more rapid resolution of thromboembolus compared with heparin alone. Thrombolytic agents also result in superior early resolution of lung scan abnormalities and more rapid hemodynamic improvement. With careful selection of patients, it has become evident that the incidence of hemorrhage can be greatly decreased from that seen in the early trials. However, patients with VTE who receive thrombolytic therapy have a 1 to 2% risk of intracranial bleeding. Furthermore, there is as yet no clearly established short-term mortality effect with a thrombolytic agent in PE.²⁰³ This finding is not surprising, since previous trials were mostly designed primarily to establish the thrombolytic effects of these agents. The low all-cause mortality at 3 months (<10%) of patients treated with heparin and warfarin has always precluded the identification of a mortality effect of thrombolytic therapy when a relatively small number of patients are studied. Studies^{1,12-16,204} have shown that when PE is promptly diagnosed and properly treated, subsequent mortality directly due to PE is about 2%. Because of the favorable results with heparin and warfarin, thrombolytic therapy should usually be reserved for the treatment of patients with acute massive embolism who are in hemodynamically unstable condition and do not seem prone to bleeding. Confirmatory evidence is needed before one can state that thrombolytic therapy decreases the incidence of long-term disability after massive PE. These drugs may also offer benefit to younger patients with massive iliofemoral thrombosis. Epidemiologic studies must also determine the prevalence and risk factors for subsequent chronic thromboembolic pulmonary hypertension in adequately anticoagulated patients with acute PE.

In patients with DVT, urokinase and streptokinase are approved for 48 to 72 h of therapy, but in practice, regimens are quite variable, particularly when therapy is administered by catheter-directed infusion as is favored by radiologists. In PE, 12 h of urokinase treatment proved as effective as 24 h of either urokinase or streptokinase treatment, and 2 h of tPA treatment appears to be as effective as any of the older regimens.²⁰⁶⁻²⁰⁷ The question of duration of therapy can be answered only by controlled studies comparing standard and shorter courses of thrombolytic therapy.²⁰⁸⁻²¹⁰

All thrombolytic agents are administered IV in dosing regimens that are designed to activate fibrinolysis systematically in > 90% of patients. The regimens will achieve thrombolysis throughout the vasculature. Although tPA and reteplase are somewhat more fibrin specific than streptokinase and urokinase, all of these agents have the potential to lyse a fresh platelet-fibrin plug anywhere in the vasculature and cause bleeding at that site. For PE, streptokinase is recommended in a 250,000-IU loading dose followed by 100,000 IU/h for 24 h. Urokinase is recommended in a 4,400 IU/kg body weight loading dose followed by 2,200 IU/kg/h for 12 h. For PE, tPA is recommended in a 100-mg infusion over 2 h. Reteplase is not currently approved in the United States for treatment of VTE, but this agent shows promise for rapid thrombolysis.²¹¹ The drug is given in two separate IV boluses of 10 U approximately 30 min apart. For treatment of DVT, streptokinase should be given in the same manner as for PE, but the duration of therapy should probably be lengthened. Heparin should not be infused concurrently with streptokinase or urokinase. For tPA or reteplase, concurrent use of heparin is optional.

Infusion of a thrombolytic agent directly onto a venous thrombus has never been convincingly shown to be superior to infusion of the agent through a peripheral vein. There is little correlation between *in vitro* tests of fibrinolysis, on one hand, and thrombolysis or bleeding, on the other hand. This statement is particularly true for tPA and reteplase, but applies to streptokinase and urokinase as well. Consequently, when streptokinase or urokinase is infused, a thrombin time or APTT may be monitored 2 to 4 h into treatment. Prolongation of either test by 10 s indicates activation of fibrinolysis. Further laboratory monitoring of therapy is unnecessary. No laboratory monitoring of tPA or reteplase therapy is recommended. After thrombolytic therapy is completed, IV heparin therapy can be restarted once the thrombin time or APTT is shown to be less than two times normal.

Beside the lack of a proven mortality effect, thrombolytic therapy of VTE differs from therapy of myocardial infarction in another way. In myocardial infarction, thrombolytic therapy appears to dissolve the coronary thrombus in most cases, but in VTE, particularly PE, complete dissolution of thrombus is the exception.¹⁹⁹⁻¹⁹⁹ Partial dissolution is the rule because venous thromboemboli are older, larger, and more organized than coronary thrombi. Since no currently available agent or regimen usually dissolves the VTE completely, interest has turned to smaller doses and shorter duration of therapy in an effort to achieve the desired clinical effect with less bleeding. It is not yet clear that these regimens will cause less bleed-

ing, but they appear to effect comparable thrombus resolution to regimens of longer duration.^{210,211} The optimum application of thrombolytic therapy for PE remains in doubt, with some authorities arguing for treatment of only those in shock²¹² and others who would enlarge treatment indications to include those with echocardiographic evidence of right ventricular dysfunction.²¹³

3. INFERIOR VENA CAVAL PROCEDURES

The major rationale for inferior vena caval filters is the presence of a contraindication or complication of anticoagulation in an individual with or at high risk for proximal vein thrombosis of the lower extremity. Less frequent indications include recurrent thromboembolism despite adequate anticoagulation, massive hemodynamically pulmonary embolism, chronic recurrent embolism with pulmonary hypertension, and the concurrent performance of surgical pulmonary embolectomy or pulmonary endarterectomy.

The most popular method of inferior vena caval interruption is placement of a filter developed by Greenfield and Rutherford.²¹⁴ This six-legged device can be inserted through the internal jugular vein or femoral vein, and advanced into place in the inferior vena cava using fluoroscopic or ultrasonic guidance. In several large series,²¹⁴⁻²¹⁸ the long-term patency rate of the filter has been 98%. Most authorities recommend resumption of anticoagulation as soon as possible after insertion of a filter because the filter alone is not an effective treatment of VTE. Results and complications with various filters have been summarized.²¹⁷ The bird's nest filter also appears to be effective.^{218,219} However, results with the L-C medical filter and the Gunther filter appear to be less satisfactory.²²⁰⁻²²² Some authorities consider venous anatomic abnormalities, pregnancy, and thrombus proximal to the intended point of placement to be contraindications to filter insertion. Suprarenal placement of filters has been safe and effective.²²³ The ease of insertion and low complication rates of the new filters have increased the use of these devices. Filters have been placed with ultrasound guidance at the bedside of critically ill patients.²²⁴ Temporary filters are currently undergoing testing.²²⁵ Superior vena caval filters have been placed in patients with upper-extremity DVT.²²⁶

Vena caval filters have been used for primary prophylaxis of thromboembolism in patients at high risk to bleed, including patients with extensive trauma, visceral cancer, and those undergoing hip and knee surgery.^{214,227-237} These studies are uncontrolled case series, and many of them are weakened by incomplete reporting of patient outcomes. In the only (to our knowledge) randomized study²³⁸ of filter placement, the device did not prolong early or late survival in patients after a first episode of VTE, although it did reduce the rate of PE. This benefit was offset by a tendency for more recurrent DVT in those patients who received a filter.

4. PULMONARY EMBOLCTOMY

Pulmonary embolectomy continues to be performed in emergency situations when more conservative measures

have failed. If it is attempted, there is general agreement that a candidate meet the following criteria: (1) massive PE (angiographically documented if possible); (2) hemodynamic instability (shock) despite heparin and resuscitative efforts; and (3) failure of thrombolytic therapy or a contraindication to its use. Operative mortality in the era of immediately available cardiopulmonary bypass has ranged from 10 to 75% in uncontrolled retrospective case series.²³⁹⁻²⁴¹ In patients who have suffered cardiopulmonary arrest, mortality has been reported between 50% and 94%. In a recent series of 96 patients (55% of whom did not meet the criteria of hemodynamic instability), univariate analysis identified cardiac arrest and shock as predictors of mortality, and multivariate analysis confirmed the significance of cardiac arrest and underlying cardiopulmonary disease as predictors of mortality.²⁴² Reported postoperative complications include ARDS, mediastinitis, acute renal failure, and, of particular concern, severe neurologic sequelae. Pulmonary embolectomy should be considered when a patient meets the above criteria and an experienced cardiac surgical team is immediately available.²³⁹⁻²⁴²

5. CATHETER TRANSVENOUS EXTRACTION OR FRAGMENTATION OF EMBOLI

A cap device has been developed that fits over an 8.5F double-lumen, balloon-tipped steerable catheter to permit suction extraction of PE under fluoroscopy with ECG monitoring.²⁴³ In a series of 26 patients undergoing catheter embolectomy, extraction was successful in 23 patients, with a mortality rate of 27%.²⁴⁴ Two patients subsequently underwent open embolectomy. Over the same time in the same institution, six patients had open embolectomy for acute PE with a mortality of 33%.²⁴⁴ A report of catheter embolectomy in 18 patients with a 28% mortality rate has also been published.²⁴⁵

More recently, a catheter system has been devised that fragments thromboemboli by generating a Venturi effect at the catheter tip using jets of high-speed saline solution. The fragmented thrombus is then evacuated through the catheter lumen. This device looks promising, but there has been insufficient experience with it to make firm recommendations for its use.²⁴⁶ Another approach is to use a combination of pharmacologic and mechanical thrombolysis.²⁴⁷

In severely ill patients who may be candidates for catheter extraction or dissolution or for surgical embolectomy, echocardiography may provide rapid bedside diagnosis and hasten therapeutic interventions.²⁴⁸

6. PARADOXICAL EMBOLISM

The frequency of stroke and systemic embolism that is associated with VTE remains unknown. The complication most frequently occurs through a patent foramen ovale.²⁴⁹ Echocardiography is a useful diagnostic tool when paradoxical embolism is suspected.²⁵⁰ Patency of the foramen ovale should be suspected when stroke is cryptogenic or occurs in younger people. Thrombolytic therapy may be useful as acute therapy in some patients with paradoxical embolism.²⁵¹ Recently, percutaneous closure of patent foramen ovale has been demonstrated.²⁵²

7. CHRONIC PULMONARY THROMBOEMBOLISM AND PULMONARY HYPERTENSION

A few individuals with PE (probably <2%) do not resolve the process and subsequently develop pulmonary hypertension. Although primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension demonstrate similar histologic appearances in the microscopic pulmonary vessels,²⁵³ in the latter condition, the primary disorder is most likely obstruction of macroscopic pulmonary arteries by unresolved, organized emboli.²⁵⁴ If the obstructing lesions are sufficiently proximal, chronic thromboembolic pulmonary hypertension may be amenable to pulmonary thromboendarterectomy (PTE).²⁵⁵ The syndrome should be considered in anyone with unexplained dyspnea on exercise, even if pulmonary function tests reveal mild restriction.²⁵⁶ The most important preliminary diagnostic test is the pulmonary perfusion scan, which nearly invariably discloses perfusion defects, although the size of the perfusion defects frequently underestimates the extent of disease.²⁵⁷ This finding contrasts with scan findings in primary pulmonary hypertension in which perfusion defects, if present, are minimal. With an experienced surgical and medical team, surgical endarterectomy has been shown to result in significant relief of pulmonary hypertension and disability.²⁵⁸

Randomized, controlled clinical trials of PTE for patients with chronic thromboembolic pulmonary hypertension have not been performed because there is no reasonable alternative treatment. However, a recent cross-sectional survey²⁵⁹ of 308 patients evaluated at 1 year after PTE disclosed dramatic improvements in functional status and quality of life.

8. PRIMARY PULMONARY HYPERTENSION

There continues to be interest in treating primary pulmonary hypertension with antithrombotic or fibrinolytic agents,²⁶⁰⁻²⁶² although to our knowledge, there have been no randomized trials evaluating such therapies in this condition. However, the use of warfarin in patients who did not respond to calcium channel blockers appeared to result in improved survival.²⁶³ A prospective controlled study continues to be needed to confirm this observation.

RECOMMENDATIONS

1. TREATMENT OF VTE

1.1. Effective Regimens

1.1.1. We recommend that patients with DVT or PE should be treated acutely with LMW heparin, unfractionated IV heparin, or adjusted-dose subcutaneous heparin (all grade IA).

1.1.2. When unfractionated heparin is used, we recommend that the dose should be sufficient to prolong the APTT to a range that corresponds to a plasma heparin level of 0.2 to 0.4 IU/mL by protamine sulfate or 0.3 to 0.6 IU/mL by an amidolytic anti-Xa assay (grade IC+).

1.1.3. In comparison to unfractionated heparin, LMW heparin offers the major benefits of convenient dosing and facilitation of outpatient treatment. LMW heparin treatment may result in slightly less recurrent VTE and may offer a survival benefit in patients with cancer. We recommend that clinicians use LMW heparin over unfractionated heparin (grade 2B).

1.2. Initial Anticoagulation With Heparin

1.2.1. We recommend that treatment with heparin or LMW heparin should be continued for at least 5 days and that oral anticoagulation should be overlapped with heparin or LMW heparin for at least 4 to 5 days (grade 1A) in comparison with treatment for 10 days).

Remark: For most patients, treatment with warfarin can be started together with heparin or LMW heparin. The heparin product can be discontinued on day 5 or day 6 if the INR has been therapeutic for 2 consecutive days.

1.2.2. For massive PE or severe iliofemoral thrombosis, we recommend a longer period of heparin therapy of approximately 10 days (grade 1C).

1.3. Long-term Anticoagulation

1.3.1. We recommend that oral anticoagulant therapy should be continued for at least 3 months to prolong the prothrombin time to a target INR of 2.5 (range, 2.0 to 3.0). When oral anticoagulation is either contraindicated or inconvenient, a treatment dose of LMW heparin or unfractionated adjusted-dose heparin to prolong the APTT to a time that corresponds to a therapeutic plasma heparin level for most of the dosing interval should be used (grade 1A).

1.3.2. We recommend that patients with reversible or time-limited risk factors should be treated for at least 3 months (grade 1A).

1.3.3. We recommend that patients with a first episode of idiopathic VTE should be treated for at least 6 months (grade 1A).

1.3.4. For patients with recurrent idiopathic VTE or a continuing risk factor such as cancer, antithrombin deficiency, or anticardiolipin antibody syndrome, we recommend treatment for 12 months or longer (grade 1C).

Remark: Duration of therapy continues to be individualized in patients with deficiency of proteins C or S, multiple thrombophilic conditions, homocystinemia, and homozygous factor V Leiden.

1.3.5. We recommend that symptomatic isolated calf vein thrombosis should be treated with anticoagulation for at least 6 to 12 weeks (grade 1A). If for any reason anticoagulation is not administered, we recommend that serial noninvasive studies of the lower extremity should be performed over the next 10 to 14 days to assess for proximal extension of thrombus (grade 1C).

2. Thrombolytic Therapy

Remark: The use of thrombolytic agents in the treatment of VTE continues to be highly individualized, and clinicians should have some latitude in using these agents. In general, patients with hemodynamically unstable PE or massive iliofemoral thrombosis, who are at low risk to bleed, are the most appropriate candidates.

3. Inferior Vena Caval Procedures

3.1. We recommend placement of an inferior vena caval filter when there is a contraindication or complication of anticoagulant therapy in an individual with or at high risk for proximal vein thrombosis or PE (grade 1C+). We also recommend placement of an inferior vena caval filter for recurrent thromboembolism that occurs despite adequate anticoagulation, for chronic recurrent embolism with pulmonary hypertension, and with the concurrent performance of surgical pulmonary embolectomy or pulmonary thromboendarterectomy (grade 1C).

REFERENCES

- Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. *JAMA* 1998; 279:458-462.
- Brandjes DP, Buller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. *Lancet* 1997; 349:759-762.
- Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. *Thromb Haemost* 1988; 60:457-462.
- Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. *Biochem J* 1989; 257:143-150.
- Simon TL, Hyers TM, Gaston JP, et al. Heparin pharmacokinetics: increased requirements in pulmonary embolism. *Br J Haematol* 1978; 39:111-120.
- Barratt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled clinical trial. *Lancet* 1969; i:1309-1312.
- Kernohan RJ, Todd C. Heparin therapy in thromboembolic disease. *Lancet* 1966; i:621-623.
- Alpert JS, Smith R, Carlson CJ, et al. Mortality in patients treated for pulmonary embolism. *JAMA* 1976; 236:1477-1480.
- Kanis JA. Heparin in the treatment of pulmonary thromboembolism. *Thromb Haemost* 1974; 32:517-527.
- Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. *N Engl J Med* 1986; 315:1109-1114.
- Brandjes DPM, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. *N Engl J Med* 1992; 327:1485-1489.
- Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med* 1996; 334:677-681.

- 13 Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. *N Engl J Med* 1996; 334:682-687
- 14 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 1997; 337:657-662
- 15 Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. *N Engl J Med* 1997; 337:663-669
- 16 Hull RD, Raskob GE, Brandt RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. *Arch Intern Med* 2000; 160:229-236
- 17 Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial. *Ann Intern Med* 1987; 107:441-445
- 18 Pini M, Patacchioli A, Quintavalla R, et al. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial. *Thromb Haemostasis* 1990; 64:222-226
- 19 Anderson G, Fagrell B, Holmgren K, et al. Subcutaneous administration of heparin: a randomized comparison with intravenous administration of heparin to patients with deep-vein thrombosis. *Thromb Res* 1982; 27:631-639
- 20 Lagerstedt CI, Olsson C-G, Fagher BO, et al. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet* 1985; 2:515-518
- 21 Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. *N Engl J Med* 1997; 336:393-395
- 22 White RH, McGowan JE, Daschbach MM, et al. Diagnosis of deep vein thrombosis using duplex ultrasound. *Ann Intern Med* 1989; 111:297-304
- 23 Hirsh J, van Aken WG, Gallus AS. Heparin kinetics in venous thrombosis and pulmonary embolism. *Circulation* 1976; 53:691-695
- 24 Cipolle R, Seifert R, Neilan B, et al. Heparin kinetics: variables related to disposition and dosage. *Clin Pharmacol Ther* 1981; 29:387-393
- 25 Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. *J Lab Clin Med* 1973; 81:298-310
- 26 Heiden D, Mielke CH, Rodvén R. Impairment by heparin of primary hemostasis and platelet (^{14}C) 5-hydroxytryptamine release. *Br J Haematol* 1977; 36:427-436
- 27 Fernandez F, Nguyen P, van Ryn J, et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. *Thromb Res* 1986; 43:491-495
- 28 Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. *Ann NY Acad Sci* 1989; 556:245-254
- 29 Glazier RL, Crowell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. *JAMA* 1976; 236:1365-1367
- 30 Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: controlled prospective trial. *N Engl J Med* 1975; 292:1046-1050
- 31 Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. *Am Heart J* 1979; 97:155-158
- 32 Mant MJ, Thong KL, Birtwhistle RV, et al. Hemorrhagic complications of heparin therapy. *Lancet* 1977; 1:1133-1135
- 33 Fagher B, Lundh B. Heparin treatment of deep vein thrombosis. *Acta Med Scand* 1981; 210:357-361
- 34 Wilson JE III, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. *Am J Med* 1981; 70:808-816
- 35 Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. *N Engl J Med* 1972; 287:325-327
- 36 Coon WW, Willis FW III, Symons MJ. Assessment of anticoagulant therapy of pulmonary thromboembolism. *Ann Surg* 1969; 197:559-568
- 37 The Urokinase Pulmonary Embolism Trial. A national cooperative study. *Circulation* 1973; 47(suppl):1-100
- 38 Gitel SN, Wessler S. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implication. *J Lab Clin Med* 1979; 94:481-488
- 39 Wessler S, Reimer L, Freiman R, et al. Serum-induced thrombosis: studies of its induction and evolution under controlled conditions *in vivo*. *Circulation* 1959; 20:264-274
- 40 Chui HM, Hirsh J, Yung WL, et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. *Blood* 1977; 49:171-184
- 41 Morris TA, Marsh JJ, Konopka RC, et al. Antibodies against the fibrin B-chain amino terminus detect active canine venous thrombi. *Circulation* 1997; 96:3173-3179
- 42 Foller L, Tomson JM, Yee KF. Heparin and partial thromboplastin time: an international survey. *Br J Haematol* 1980; 44:161-165
- 43 Triplett DA, Harris CS, Koepke JA. The effect of heparin on the activated partial thromboplastin time. *Am J Clin Pathol* 1978; 70:556-559
- 44 Hull RD, Raskob GE, Brandt RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. *Arch Intern Med* 1997; 157:2317-2321
- 45 Hull RD, Raskob GE, Brandt RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. *Arch Intern Med* 1997; 157:2562-2568
- 46 Wester JP, de Valk HW, Nieuwenhuis HK, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. *Thromb Haemostasis* 1996; 76:682-688
- 47 Anand S, Ginsberg JS, Kearon C, et al. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. *Arch Intern Med* 1996; 156:1677-1681
- 48 Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. *Arch Intern Med* 1999; 159:2029-2032
- 49 Young E, Pruis M, Levine MN, et al. Heparin binding to plasma proteins: an important mechanism for heparin resistance. *Thromb Haemostasis* 1992; 67:639-643
- 50 Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. *Ann Intern Med* 1993; 119:104-109
- 51 Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular weight heparin vs intravenous heparin: an economic perspective. *Arch Intern Med* 1997; 157:289-294
- 52 van den Belt AGM, Bossuyt PMM, Prius MH, et al. Replacing inpatient care by out-patient care in the treatment of deep venous thrombosis: an economic evaluation. *Thromb Haemostasis* 1998; 79:259-263
- 53 Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. *Ann Intern Med* 1999; 130:789-799

- 54 O'Brien BO, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. *Arch Intern Med* 1999; 159: 2295-2304
- 55 Dolovich LR, Ginsberg JS, Douketts JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. *Arch Intern Med* 2000; 160:181-188
- 56 Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. *Arch Intern Med* 1994; 154:40-56
- 57 Barbour LA, Smith JM, Marlar RA. Heparin levels to guide thromboembolism prophylaxis during pregnancy. *Am J Obstet Gynecol* 1995; 173:1860-1873
- 58 Penner JA. Experience with a thrombin clotting time assay for measuring heparin activity. *Am J Clin Pathol* 1974; 61:645-653
- 59 Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels: time to reassess guidelines for heparin assays. *Arch Intern Med* 1997; 157:2475-2479
- 60 Krulder JWM, de Boer A, van den Besselaar AMHP, et al. Diurnal rhythm in anticoagulant effect of heparin during low dose constant rate infusion. *Thromb Haemost* 1992; 68:30-32
- 61 Kearon C, Johnston M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. *Arch Intern Med* 1998; 158:1140-1143
- 62 Delorme MA, Inwood MJ, O'Keefe B. Sensitivity of the thrombin clotting time and activated partial thromboplastin time to low level of antithrombin III during heparin therapy. *Clin Lab Haematol* 1990; 12:433-436
- 63 Hirsh J. Heparin. *N Engl J Med* 1991; 324:1565-1574
- 64 Bjornsson TO, Wolfram BS, Kitchell BD. Heparin kinetics determined by three assay methods. *Clin Pharmacol Ther* 1982; 31:104-113
- 65 Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. *Arch Intern Med* 1988; 148:1321-1325
- 66 Hull RD, Raskob GE, Lemaire J, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. *Arch Intern Med* 1992; 152:1589-1595
- 67 Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram: a randomized controlled trial. *Ann Intern Med* 1993; 119:874-881
- 68 Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. *Arch Intern Med* 1991; 151:333-337
- 69 Gallus A, Jackman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. *Lancet* 1986; 2:1293-1296
- 70 Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. *N Engl J Med* 1990; 322:1260-1264
- 71 Ansell J, Slepchuk N Jr, Kumar R, et al. Heparin-induced thrombocytopenia: a prospective study. *Thromb Haemost* 1980; 43:61-65
- 72 Babcock KB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. *N Engl J Med* 1976; 295:237-241
- 73 Bell WR, Royall RM. Heparin-induced thrombocytopenia: a comparison of three heparin preparations. *N Engl J Med* 1980; 303:902-907
- 74 Bell WR, Tomasulo PA, Alving BM, et al. Thrombocytopenia occurring during the administration of heparin: a prospective study in 52 patients. *Ann Intern Med* 1976; 85:155-160
- 75 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. *Prog Hemostasis Thromb* 1991; 10:1-34
- 76 Cines DB, Tomasulo A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. *N Engl J Med* 1987; 316:581-589
- 77 Warkentin TE, Elavathil LJ, Hayward CPM. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. *Ann Intern Med* 1997; 127: 804-812
- 78 White FW, Sudd JR, Nensel RE. Thrombotic complications of heparin therapy. *Ann Surg* 1979; 190:595-608
- 79 Griffith CC, Nichols G, Asher J, et al. Heparin osteoporosis. *JAMA* 1965; 193:91-94
- 80 Jaffe MD, Willis FW III. Multiple fracture associated with long-term heparin therapy. *JAMA* 1965; 193:158-160
- 81 Sackler JT, Liu L. Heparin-induced osteoporosis. *Br J Radiol* 1973; 46:458-460
- 82 Squires JW, Finch LW. Heparin-induced spinal fractures. *JAMA* 1979; 241:2417-2418
- 83 Wise FW, Hall AJ. Heparin-induced osteopenia in pregnancy. *BMJ* 1980; 2:110-111
- 84 Edes TE, Sunderrajan EV. Heparin-induced hyperkalemia. *Arch Intern Med* 1985; 145:1070-1072
- 85 Schwartz KA, Royer G, Kaufman DB, et al. Complications of heparin administration in normal individuals. *Am J Hematol* 1985; 19:355-363
- 86 Dukes GE Jr, Sanders SW, Russo J Jr, et al. Transaminase elevations in patients receiving bovine or porcine heparin. *Ann Intern Med* 1984; 100:646-650
- 87 Minar E, Ehringer H, Hirschl M, et al. Transaminasenanstieg: eine weitgehend unbekannte Nebenwirkung der Heparintherapie. *Dtsch Med Wochenschr* 1980; 105:1713-1717
- 88 Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. *Am J Med* 1990; 88:235-240
- 89 Hull RD, Delmore TJ, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. *N Engl J Med* 1978; 301:855-858
- 90 Fearnside MR, Reeve TS, Coupland GAE. Long-term anti-coagulation in venous thromboembolic disease by subcutaneous calcium-heparin injection. *Med J Aust* 1971; 2:891
- 91 Hull RD, Delmore TJ, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. *N Engl J Med* 1982; 306:189-194
- 92 Hyers TM. Venous thromboembolism: state of the art. *Am J Respir Crit Care Med* 1999; 159:1-14
- 93 Rooke TW, Osmundson FJ. Heparin and the in-hospital management of deep venous thrombosis: cost considerations. *Mayo Clin Proc* 1986; 61:198-204
- 94 Dunn AS, Collier B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. *Am J Med* 1999; 106:660-669
- 95 Salzman EW. Low molecular weight heparin: is small beautiful? *N Engl J Med* 1986; 315:957-959
- 96 Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin. *Drugs* 1990; 40: 498-530
- 97 Aiaich M, Michaud A, Ballan JL, et al. A new low molecular weight heparin derivative, *in vitro* and *in vivo* studies. *Thromb Res* 1983; 31:611-621
- 98 Bara L, Billand E, Gramond C, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. *Thromb Res* 1985; 39:631-636
- 99 Bergqvist D, Hedner U, Sjörin E, et al. Anticoagulant effects of two types of low molecular weight heparin administered


- subcutaneously. *Thromb Res* 1983; 32:381-391
- 100 Bratt G, Tornebohm E, Widlund L, et al. Low molecular weight heparin (Kabi 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. *Thromb Res* 1986; 42:613-620
- 101 Frydman AM, Bara L, LeRoux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. *J Clin Pharmacol* 1988; 28:609-618
- 102 Matzsch T, Bergqvist D, Hedner U, et al. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. *Thromb Haemost* 1987; 57:97-101
- 103 Harenberg J, Wurzer M, Zimmermann R, et al. Bioavailability and antagonization of the low molecular weight heparin CY216 in man. *Thromb Res* 1986; 44:549-554
- 104 Casele HL, Laffer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. *Am J Obstet Gynecol* 1999; 181:1113-1117
- 105 Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. *Thromb Res* 1984; 35:613-625
- 106 Carter CJ, Kelton JF, Hirsh J, et al. Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. *Thromb Res* 1981; 21:169-174
- 107 Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. *Blood* 1982; 59: 1239-1245
- 108 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. *Thromb Res* 1982; 25:475-485
- 109 A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: a collaborative European multicentre study. *Thromb Haemost* 1991; 65:251-256
- 110 Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. *Circulation* 1989; 80:935-940
- 111 Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). *Thromb Haemost* 1990; 64:506-510
- 112 Bratt G, Tornebohm E, Granqvist S, et al. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. *Thromb Haemost* 1985; 54:813-817
- 113 Holm HA, Ly E, Handeland GF, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. *Haemostasis* 1986; 16:30-37
- 114 Lockner D, Bratt G, Tornebohm E, et al. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. *Haemostasis* 1986; 16:25-29
- 115 Prandoni P, Vigo M, Cattelan AM, et al. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). *Haemostasis* 1990; 20(suppl 1):220-223
- 116 Albada J, Nieuwenhuis HK, Sixma JJ. Comparison of intravenous standard heparin and Fragmin in the treatment of venous thromboembolism: a randomized double-blind study [abstract]. *Thromb Res* 1987; 6(suppl):14
- 117 Bratt G, Aberg W, Tornebohm E, et al. Subcutaneous KABI 2165 in the treatment of deep venous thrombosis of the leg [abstract]. *Thromb Res* 1987; 7(suppl):24
- 118 Simonneau G, Charbonnier E, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. *Arch Intern Med* 1993; 153:1541-1546
- 119 Handeland GF, Abildgaard U, Holm HA, et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. *Eur J Clin Pharmacol* 1990; 39:107-112
- 120 Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. *Haemostasis* 1990; 20(suppl 1): 205-219
- 121 Huet Y, Janvier G, Bendris PH, et al. Treatment of established venous thromboembolism with enoxaparin: preliminary report. *Acta Chir Scand* 1990; 556(suppl):116-120
- 122 Janvier G, Wincock S, Dugrais G, et al. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 232). *Haemostasis* 1987; 7:49-58
- 123 Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal vein thrombosis. *Lancet* 1992; 339:441-445
- 124 Hull RD, Rasbok GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the initial treatment of proximal-vein thrombosis. *N Engl J Med* 1992; 326:975-982
- 125 Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. *Thromb Haemost* 1994; 72:186-190
- 126 Flessinger JN, Lopez-Fernandez M, Catterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. *Thromb Haemost* 1996; 76:195-199
- 127 Luomanmaki K, Granqvist S, Hallert G, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. *J Intern Med* 1996; 240:85-92
- 128 Kirchmaier CM, Wolf H, Scheafer H, et al. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis: Certoparin Study Group. *Int Angiol* 1998; 17:135-145
- 129 Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. *Thromb Haemost* 1995; 74:1432-1435
- 130 Lopacinski S, Meissner AJ, Filipceki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. *Thromb Haemost* 1992; 68:14-18
- 131 Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. *Am J Med* 1996; 100:260-277
- 132 Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. *Ann Intern Med* 1999; 130:800-809
- 133 Weitz JI, Hudoba M, Massel D, et al. Clot bound thrombus is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. *J Clin Invest* 1990; 86:385-391

- 134 Heras M, Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. *Circulation* 1989; 79:657-665
- 135 Agnelli G, Pascucci C, Cosmi B, et al. The comparative effects of recombinant hirudin (CCP-39393) and standard heparin on thrombus growth in rabbits. *Thromb Haemost* 1990; 63:204-207
- 136 Eriksson BI, Wille-Jørgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. *N Engl J Med* 1997; 337:1329-1335
- 137 Schiele F, Vuillenet A, Kramarz F, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. *Am J Hematol* 1995; 50: 20-25
- 138 Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. *Circulation* 1999; 99:73-80
- 139 Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and thrombotic syndrome. *Semin Thromb Hemost* 1997; 23:197-202
- 140 Stenflo J. Vitamin K, prothrombin, and gamma-carboxyglutamic acid. *Adv Enzymol* 1978; 46:1-31
- 141 Bell RW. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. *Fed Proc* 1978; 37:2599-2604
- 142 Esmon CT, Suttie JW, Jackson CM. The functional significance of vitamin K action: difference in phospholipid binding between normal and abnormal prothrombin. *J Biol Chem* 1975; 250:4095-4099
- 143 Hemker HC, Veldkamp JJ, Loeliger CA. Kinetic aspects of the interaction of blood-clotting enzymes: III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. *Thromb Haemost* 1968; 19:346-363
- 144 Hemker HC, Muller AD. Kinetic aspects of the interaction of blood clotting enzymes: VI. Localization of the site of blood coagulation inhibition by the protein induced by vitamin K absence (PIVKA). *Thromb Haemost* 1968; 20: 78-87
- 145 O'Reilly RA, Aggeler PM, Leong LS. Studies on coumarin anticoagulant drugs: pharmacodynamics of warfarin in man. *J Clin Invest* 1963; 42:1542-1557
- 146 Viganò S, Mannucci PM, Solanís S, et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. *Br J Haematol* 1984; 57:213-220
- 147 Wessler S, Gitel SN. Warfarin: from bedside to bench. *N Engl J Med* 1984; 311:645-652
- 148 Khamashta MA, Cuadrado MJ, Mujic R, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med* 1995; 332:993-997
- 149 O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. *Circulation* 1968; 38:169-177
- 150 Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. *Ann Intern Med* 1997; 126:133-136
- 151 Loeliger EA. Progress in the control of oral anticoagulant therapy. *Thromb Haemost* 1972; 28:109-119
- 152 Branson HE. Prothrombin time after heparin removal: application to monitoring simultaneous anticoagulation with heparin and coumarin. *Am J Clin Pathol* 1979; 71:665-667
- 153 van den Besselaar AM, Meeuwisse-Braun J. Enzymatic elimination of heparin from plasma for activated partial thromboplastin time and prothrombin time testing. *Blood Coagul Fibrinolysis* 1993; 4:635-638
- 154 Sevitt S, Innes D. Prothrombin time and Thrombotest in injured patients on prophylactic anticoagulant therapy. *Lancet* 1964; 1:124-129
- 155 Danielson CFM, Davis K, Jones G, et al. Effect of citrate concentration in specimen collection tubes on the international normalized ratio. *Arch Pathol Lab Med* 1997; 121: 956-959
- 156 Hirsh J. Oral anticoagulant drugs. *N Engl J Med* 1991; 324:1865-1875
- 157 Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. *JAMA* 1965; 194:127-129
- 158 Gitel SN, Wessler S. Dose-dependent effect of warfarin in rabbits. *Blood* 1983; 61:435-438
- 159 Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. *N Engl J Med* 1982; 307:1676-1681
- 160 Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. *BMJ* 1991; 303:219-220
- 161 Holmgren K, Anderson C, Fagrell B, et al. One month versus six month therapy with oral anticoagulants after symptomatic deep vein thrombosis. *Acta Med Scand* 1985; 218:279-284
- 162 Bynum LJ, Wilson JE. Low-dose heparin therapy in the long-term management of venous thromboembolism. *Am J Med* 1979; 67:553-556
- 163 Coon WW, Willis FW III. Hemorrhagic complications of anticoagulant therapy. *Arch Intern Med* 1974; 133:386-392
- 164 O'Sullivan EF, Hirsh J. Duration of anticoagulation therapy in venous thromboembolism. *Med J Aust* 1978; 2:1104-1107
- 165 Research Committee of the British Thrombotic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. *Lancet* 1992; 340:873-876
- 166 Kearns C, Gent M, Hirsh J, et al. Extended anticoagulation prevented recurrences after a first episode of idiopathic venous thromboembolism. *N Engl J Med* 1999; 340:901-907
- 167 Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. *N Engl J Med* 1995; 332:1661-1665
- 168 Moschos CB, Wang FCV, Size HS. Controlled study of the effective level of long-term anticoagulation. *JAMA* 1964; 190:799-804
- 169 Zweifler AJ. Relation of prothrombin concentration to bleeding during anticoagulant therapy: its importance in detection of latent organic lesions. *N Engl J Med* 1962; 267:283-285
- 170 Boekhout-Mussert MJ, Briet E, van Brummelen P, et al. Arterial thromboembolic complications with aortic ball valve prosthesis. *Am Heart J* 1978; 95:270-272
- 171 Borckgrevenk CF. Long term anticoagulant therapy in angina pectoris and myocardial infarction. *Acta Med Scand* 1960; 168(suppl 359):1-52
- 172 Gitel SN, Stephenson RC, Wessler S. *In vitro* and *in vivo* correlation of clotting protease activity: effect of heparin. *Proc Natl Acad Sci U S A* 1977; 74:3028-3032
- 173 Francis CW, Marder VJ, McCollister EC, et al. Two step warfarin therapy. *JAMA* 1963; 249:374-378
- 174 Rozenberg MC, Firkin BC. Thrombotest and prothrombin time: a controlled clinical trial. *Aust Ann Med* 1965; 4:3
- 175 Taberner DA, Poller L, Burslem RW, et al. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. *BMJ* 1978; 1:272-274

- 176 Wessler S, Gitel SN, Bank H, et al. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. *Thromb Haemost* 1979; 40:486-498
- 177 Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. *Ann Intern Med* 1997; 127:177-185
- 178 Crowther MA, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. *Thromb Haemost* 1998; 79:1116-1118
- 179 Faraci PA, Detering RA, Stein AM, et al. Warfarin induced necrosis of the skin. *Surg Gynecol Obstet* 1978; 146:695-700
- 180 Koch-Weser J. Coumarin necrosis. *Ann Intern Med* 1968; 68:1365-1367
- 181 Martin BF, Phillips JC. Gangrene of the female breast with anticoagulant therapy: report of two cases. *Am J Clin Pathol* 1970; 53:622-626
- 182 McGeehe WC, Klotz TA, Epstein DJ, et al. Coumarin necrosis associated with hereditary protein C deficiency. *Ann Intern Med* 1984; 100:59-60
- 183 Kazmier FJ. Thromboembolism, coumarin necrosis, and protein C. *Mayo Clin Proc* 1985; 60:673-674
- 184 Everett RN, Jones FL. Warfarin-induced skin necrosis: a cutaneous sign of malignancy? *Postgrad Med* 1986; 79:97-103
- 185 Hall JC, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. *Am J Med* 1980; 68:122-140
- 186 Stevenson RE, Burton OM, Forlano CJ, et al. Hazards of oral anticoagulants during pregnancy. *JAMA* 1980; 243: 1549-1551
- 187 McKenna R, Cale ER, Vaan U. Is warfarin sodium contraindicated in the lactating mother? *J Pediatr* 1983; 103:325-327
- 188 Lao TT, DeSwiet M, Letsky E, et al. Prophylaxis of thromboembolism in pregnancy: an alternative. *Br J Obstet Gynaecol* 1985; 92:202-206
- 189 Togia MR, Weg JC. Venous thromboembolism during pregnancy. *N Engl J Med* 1996; 335:108-114
- 190 Hull RD, Raskob GE, Hirsh J, et al. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. *JAMA* 1984; 252:235-239
- 191 Marder VJ, Sherry S. Thrombolytic therapy: current status. *N Engl J Med* 1988; 318:1512-1520; 1558-1594
- 192 Urokinase Pulmonary Embolism Trial phase I results. *JAMA* 1970; 214:2163-2172
- 193 Urokinase Streptokinase Pulmonary Embolism Trial phase II results. *JAMA* 1974; 229:1606-1613
- 194 Marder VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. *Ann Intern Med* 1979; 90:802-808
- 195 Goldhaber SZ, Kessler CM, Hitt J, et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. *Lancet* 1988; 2:293-298
- 196 Amesen H, Holseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective trial. *Acta Med Scand* 1982; 211:65
- 197 Elliott MS, Immanueln JP, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. *Br J Surg* 1979; 66:838-843
- 198 Watz R, Savidge CF. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. *Acta Med Scand* 1979; 205:293-298
- 199 Common HH, Seaman AR, Rosch J, et al. Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study. *Angiology* 1976; 27:645-654
- 200 Johanson L, Nylander G, Hedner U, et al. Comparison of streptokinase with heparin: late results in the treatment of deep vein thrombosis. *Acta Med Scand* 1979; 206:93-98
- 201 Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy of acute deep vein thrombosis. *Am J Surg* 1985; 10:54-63
- 202 Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med* 1996; 125:1-7
- 203 Sharma GVRK, Burleson VA, Sasahara AA, et al. Effect of thrombolytic therapy on pulmonary capillary blood volume in patients with pulmonary embolism. *N Engl J Med* 1980; 303:842-845
- 204 Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. *N Engl J Med* 1992; 326:1240-1245
- 205 Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. *Am J Med* 1990; 88:235-240
- 206 Goldhaber SZ, Haire WD, Feldstein ML. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. *Lancet* 1993; 341:507-511
- 207 Goldhaber SZ, Agnelli G, Levine MN. Reduced dose alteplase vs conventional alteplase infusion for pulmonary embolism: thrombolysis: an international multicenter randomized trial: Bolus Alteplase Pulmonary Embolism Group. *Chest* 1994; 106:718-724
- 208 Cella G, Pulla A, Sasahara AA. Controversies of different regimens of thrombolytic therapy in acute pulmonary embolism. *Semin Thromb Hemost* 1987; 13:163-170
- 209 Verstraete M, Miller GAH, Bounameaux H, et al. Treatment of acute massive pulmonary embolism. *Circulation* 1988; 77:353-360
- 210 Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in acute pulmonary embolism. *Chest* 1990; 98:1473-1479
- 211 Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. *Am Heart J* 1999; 138:39-44
- 212 Dalen JE, Alpert JS. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? when is it indicated? *Arch Intern Med* 1997; 157:2550-2556
- 213 McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. *Am J Cardiol* 1986; 78:469-473
- 214 Greenfield LJ, Rutherford RB. Recommended reporting standards for vena caval filter placement and patient follow-up: Vena Caval Filter Consensus Conference. *J Vasc Interv Radiol* 1999; 10:1013-1019
- 215 Fink JA, Jones BT. The Greenfield filter as the primary means of therapy in venous thromboembolic disease. *Surg Gynecol Obstet* 1991; 172:253-282
- 216 Leach TA, Pastena JA, Swan KG, et al. Surgical prophylaxis for pulmonary embolism. *Am Surg* 1994; 60:292-295
- 217 Dorfman GS. Percutaneous inferior vena caval filters. *Radiology* 1990; 174:987-992
- 218 Hubbard KP, Roehm JO Jr, Abbuzzese JL. The bird's nest filter: an alternative to long-term oral anticoagulation in patients with advanced malignancies. *Am J Clin Oncol* 1994; 17:115-117
- 219 Lord RS, Benn I. Early and late results after bird's nest filter placement in the inferior vena cava: clinical and duplex ultrasound follow up. *Aust N Z J Surg* 1994; 64:106-114
- 220 Murphy TP, Dorfman GS, Yedlicka JW, et al. LGM vena cava filter: objective evaluation of early results. *J Vasc Interv Radiol* 1991; 2:107-115
- 221 Millward SF, Peterson RA, Moher D, et al. LGM (Vena Tech) vena caval filter: experience at a single institution. *J*

- Vasc Interv Radiol 1994; 5:351-356
- 222 Bull PG, Mendel H, Schlegl A. Gunther vena caval filter: clinical appraisal. *J Vasc Interv Radiol* 1992; 3:395-399
- 223 Greenfield LJ, Proctor MC. Suprarenal filter placement. *J Vasc Surg* 1998; 28:432-438
- 224 Tola JC, Holtzman R, Lottenberg L. Bedside placement of inferior vena cava filters in the intensive care unit. *Am Surg* 1999; 65:833-837
- 225 Linsenmaier U, Rieger J, Schenk F, et al. Indications, management, and complications of temporary inferior vena cava filters. *Cardiovasc Interv Radiol* 1998; 21:464-469
- 226 Spence LK, Girona MG, Malde HM, et al. Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters. *Radiology* 1999; 210:53-58
- 227 Greenfield LJ, Cho KJ, Proctor M, et al. Results of a multicenter study of the modified hook-titanium Greenfield filter. *J Vasc Surg* 1991; 14:253-257
- 228 Rohrer MJ, Scheidler MG, Wheeler Brownell H, et al. Extended indications for placement of an inferior vena cava filter. *J Vasc Surg* 1989; 10:44-50
- 229 Colucsek PJ, Garrett WV, Thompson JE, et al. Interruption of the vena cava by means of the Greenfield filter: expanding the indications. *Surgery* 1988; 103:111-117
- 230 Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. *Surgery* 1991; 109:12-15
- 231 Calligaris KD, Bergen WS, Haut MJ, et al. Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. *Ann Vasc Surg* 1991; 5:186-189
- 232 Emerson RH, Cross R, Head WC. Prophylactic and early therapeutic use of the Greenfield filter in hip and knee joint arthroplasty. *J Arthroplasty* 1991; 6:129-135
- 233 Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer related hypercoagulable states: a risky business. *J Gen Intern Med* 1993; 8:476-486
- 234 Rogers FB, Shackford SR, Wilson J, et al. Prophylactic vena cava filter insertion in severely injured trauma patients: indications and preliminary results. *J Trauma* 1993; 35:637-641
- 235 Rosenthal D, McKitsey JF, Levy AM, et al. Use of the Greenfield filter in patients with major trauma. *Cardiovasc Surg* 1994; 2:52-55
- 236 Webb LX, Rush PT, Fuller SB, et al. Greenfield filter prophylaxis of pulmonary embolism in patients undergoing surgery for acetabular fracture. *J Orthop Trauma* 1992; 6:139-145
- 237 Collins DN, Barnes CL, McCowan TC, et al. Vena caval filter use in orthopedic trauma patients with recognized preoperative venous thromboembolic disease. *J Orthop Trauma* 1992; 6:135-138
- 238 Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *N Engl J Med* 1998; 338:409-415
- 239 Meyer G, Tamisier D, Sors H, et al. Pulmonary embolism: a 20 year experience at one center. *Ann Thorac Surg* 1991; 51:232-236
- 240 Gray HH, Morgan JM, Paneth M, et al. Pulmonary embolism for acute massive pulmonary embolism: an analysis of 71 cases. *Br Heart J* 1988; 60:196-200
- 241 Clarke DB, Abrams LD. Pulmonary embolism: a 25 year experience. *J Thorac Cardiovasc Surg* 1986; 92:442-445
- 242 Ullmann M, Hemmer W, Hannekum A. The urgent pulmonary embolism: mechanical resuscitation in the operating theatre determines the outcome. *Thorac Cardiovasc Surg* 1999; 47:5-8
- 243 Stewart JR, Greenfield LJ. Transvenous vena caval filtration and pulmonary embolism. *Surg Clin North Am* 1982; 62:411-430
- 244 Greenfield LJ, Langham MR. Surgical approaches to thromboembolism. *Br J Surg* 1984; 71:968-970
- 245 Timst J-F, Reynaud P, Meyer G, et al. Pulmonary embolism by catheter device in massive pulmonary embolism. *Chest* 1991; 100:655-658
- 246 Koning R, Oribier A, Gerber L, et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. *Circulation* 1997; 96:2498-2500
- 247 Fava M, Loyola S, Flores P, et al. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. *J Interv Radiol* 1997; 8:261-266
- 248 Tapson VF, Davidson CJ, Kisslo KB, et al. Rapid visualization of massive pulmonary emboli utilizing intravascular ultrasound. *Chest* 1994; 105:888-890
- 249 d'Audiffret A, Shenoy SS, Ricotta JJ, et al. The role of thrombolytic therapy in the management of paradoxical embolism. *Cardiovasc Surg* 1998; 6:302-306
- 250 Quere JP, Tribouillet C, Adam MC, et al. Paradoxical embolism following acute pulmonary embolism: diagnosis and outcome. *Int J Cardiol* 1998; 64:131-135
- 251 Aboyan V, Lacroix P, Ostya E, et al. Diagnosis and management of entrapped embolus through a patent foramen ovale. *Eur J Cardiothorac Surg* 1998; 14:624-628
- 252 Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism. *Circulation* 2000; 101:893-898
- 253 Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. *Chest* 1993; 103:685-692
- 254 Fedullo PF, Auger WR, Channick RN, et al. Chronic thromboembolic pulmonary hypertension. *Clin Chest Med* 1995; 16:353-374
- 255 Jamieson SW, Auger WR, Fedullo PF, et al. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. *J Thorac Cardiovasc Surg* 1993; 106:116-126 (discussion 126-127)
- 256 Morris TA, Auger WR, Ysaac MZ, et al. Parenchymal scarring is associated with restrictive spirometric effects in patients with chronic thromboembolic pulmonary hypertension. *Chest* 1996; 110:399-403
- 257 Ryan KL, Fedullo PF, Davis GB, et al. Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. *Chest* 1988; 93:1180-1185
- 258 Jamieson SW, Auger WR, Fedullo PF, et al. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. *J Thorac Cardiovasc Surg* 1993; 106:116-126
- 259 Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. *Am J Respir Crit Care Med* 1999; 160:523-528
- 260 Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation* 1984; 70:580-587
- 261 Rich S, Dantzker DR, Ayers SM, et al. Primary pulmonary hypertension: a national prospective study. *Ann Intern Med* 1987; 107:216-223
- 262 Rich S, Pietra GC, Kieras K, et al. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. *Ann Intern Med* 1986; 105:499-502
- 263 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992; 327:76-81

www.chestjournal.org



CHEST

THE CARDIOPULMONARY
AND CRITICAL CARE JOURNAL

FOR PULMONOLOGISTS, CARDIOLOGISTS, CARDIOTHORACIC SURGEONS,
CRITICAL CARE PHYSICIANS, AND RELATED SPECIALISTS

HEALTH SCIENCES LIBRARY
UNIVERSITY OF WISCONSIN

FEB 08 2001

1305 Linden Drive
Madison, WI 53706

Sixth ACCP Consensus Conference on Antithrombotic Therapy

Guest Editors: James E. Dalen, MD, MPH,
Master FCCP; Jack Hirsh, MD, FCCP;
Gordon H. Guyatt, MD



CHEST

THE CARDIOPULMONARY AND CRITICAL CARE JOURNAL

Official Publication of the American College of Chest Physicians

EDITOR-IN-CHIEF

A. Jay Block, MD, Master FCCP,
Gainesville, FL

EDITORIAL BOARD

W. Michael Alberts, MD, FCCP, Tampa, FL
Nestor Angomachalis, MD, FCCP, Greece
Alejandro C. Arrolla, MD, FCCP, Cleveland,
OH

Robert A. Barbee, MD, FCCP, Tucson, AZ
Gerald L. Baum, MD, FCCP, Israel
Richard B. Berry, MD, FCCP, Gainesville, FL
Barry Dean Bortolot, MD, Tupelo, MS
Roger S. Blumenthal, MD, FCCP, Baltimore,
MD

Demosethenes E. Bouras, MD, FCCP, Greece
Mark L. Brantly, MD, Gainesville, FL
Nausherwan K. Burk, MD, FCCP, Lexington,
KY

Neil S. Cherniack, MD, Newark, NJ
W. Randolph Chittwood, Jr., MD, FCCP,
Greenville, NC

Dewey Conces, MD, FCCP, Indianapolis, IN
Burke A. Cunha, MD, FCCP, Minoia, NY
Gilbert E. D'Alonzo, DO, FCCP, Philadelphia,
PA

David R. Dantzker, MD, FCCP, New Hyde
Park, NY

Bruce Davidson, MD, MPH, FCCP, Seattle, WA
Teresta S. DeGula, MD, FCCP, Philippines
Robert J. DiBenedetto, MD, FCCP, Savannah,
GA

Guillermo de Pico, MD, FCCP, Madison, WI
Am H. Eliasson, MD, FCCP, Washington, DC
Alan M. Fein, MD, FCCP, Manhasset, NY
Stanley B. Fiel, MD, FCCP, Philadelphia, PA

Victor F. Froelicher, MD, Palo Alto, CA
Gunter Fruhmahn, MD, FCCP, Germany
Allan Garland, MD, New Brunswick, NJ
John W. Georgitis, MD, FCCP, Winston-
Salem, NC

Samuel Z. Goldhaber, MD, FCCP, Boston,
MA

Susan Harding, MD, FCCP, Birmingham, AL
Andrew Harver, PhD, Charlotte, NC
John E. Haffner, MD, FCCP, Charleston, SC

Shigeki Hitomi, MD, FCCP, Japan
Richard Irwin, MD, FCCP, Worcester, MA
Malcolm King, PhD, FCCP, Canada

Martin H. Kollef, MD, FCCP, St. Louis
Claus Kroegel, MD, PhD, FCCP, Germany
Paul A. Kvale, MD, FCCP, Detroit, MI
Abraham Joseph Layton, MD, FCCP,
Gainesville, FL

Lucas Lemberg, MD, FCCP, Miami, FL
Stuart C. Lennox, MD, FCCP, England

Brian J. Lipworth, MD, Scotland
Michael Littner, MD, FCCP, Sepulveda, CA
Joseph LoCicero III, MD, FCCP, Boston, MA

John E. Madias, MD, Elmhurst, NY
Boaz A. Markewitz, MD, FCCP, Salt Lake
City, UT

Richard A. Mintzer, MD, FCCP, Chicago, IL
Michael S. Niederman, MD, FCCP, Minoia, NY
Dario Olivieri, MD, FCCP, Italy

Gerald N. Olsen, MD, FCCP, Columbia, SC
Michael C. Pain, MD, FCCP, Australia
Harold L. Paz, MD, FCCP, New Brunswick, NJ
Henry S. Perkins, MD, San Antonio, TX
Arnaud Perrier, MD, Switzerland

Udaya Prakash, MD, FCCP, Rochester, MN
Melvin R. Pratter, MD, FCCP, Camden, NJ
Thomas A. Raffin, MD, FCCP, Stanford, CA

Bruce K. Rubin, MD, FCCP, Winston-Salem, NC
Steven Sahn, MD, FCCP, Charleston, SC
George A. Sarosi, MD, FCCP, Indianapolis, IN

John A. Sbarbaro, MD, FCCP, Denver, CO
Jeff Schnader, MD, FCCP, Dayton, OH
Molés Selman, MD, FCCP, Mexico
Morton Tavel, MD, FCCP, Indianapolis, IN

Marcel Topolsky, MD, FCCP, Israel
Francisco S. Vargas, MD, FCCP, Brazil

Joseph Varon, MD, FCCP, Houston, TX
John G. Weg, MD, FCCP, Ann Arbor, MI
Emmanuel Weitzelblum, MD, FCCP, France
Anthony Yim, DM, FCCP, Hong Kong

Publisher: Alvin Lever

Executive Editor: Stephen J. Welch

Managing Editor:

Mary Ann Brangan.

Advertising and Production Manager:

Patricia A. Micek

Senior Copy Editor: Pamela Goorsky

Medical Copy Editor: Kimberly Lynch

Circulation/Editorial Coordinator:

Barbara J. Anderson

Editorial Coordinators:

Laura Lipsey

Lisa Mathis (Florida)

National Sales Representatives

The Walchli Tauber Group, Inc.

Gary Walchli; Tel: (410) 420-0700

Steve Tauber; Tel: (410) 420-0712

FAX: (410) 420-0711

112 W. Pennsylvania Ave., Ste. 201

Bel Air MD 21014

CHEST (USPS 157-880 ISSN 0012-3692) is published monthly by the American College of Chest Physicians, 3300 Dundee Road, Northbrook IL 60062-2348. The ACCP may be contacted by telephone: (847) 498-1490; Fax: (847) 498-5460; E-mail: accp@chestnet.org; or through the World Wide Web Homepage: <http://www.chestnet.org>. Periodicals postage paid at Northbrook, IL and additional mailing offices. **POSTMASTER:** Send address changes to: CHEST, 3300 Dundee Road, Northbrook, IL 60062-2348.

ANNUAL SUBSCRIPTION RATES (Rates effective January 1, 2001.)
Persons: U.S. and Puerto Rico \$132.00; Other countries \$162.00. **Institutions:** U.S. and Puerto Rico \$174.00; Other countries \$210.00. **Special Rates for Fellows, residents, interns, nursing or respiratory therapy students, physicians-in-training:** U.S. and Puerto Rico \$60.00; Other countries \$84.00. **Special international air-shipment rate:** Members \$60.00; Nonmembers \$75.00.

SINGLE COPIES (Rates effective January 1, 2001.)
CHEST: ACCP member \$16.00; nonmember \$20.00. **Supplements:** ACCP member \$14.00; nonmember \$18.00. To order, please call 1-847-498-1400 or 1-800-343-2227.

DISCLAIMER: The statements and opinions contained in editorials and articles in this journal are solely those of the authors thereof and not of the American College of Chest Physicians, or of its officers, regents, members and employees. The appearance of advertisements or services advertised or of their effectiveness, quality, or safety are solely those of the advertisers.

The Editor-in-Chief, the American College of Chest Physicians, its officers, regents, members, and employees disclaim all responsibility for any injury to persons or property resulting from any ideas or products referred to in articles or advertisements contained in this Journal.

COPYRIGHT © 2001 by the American College of Chest Physicians

PERMISSION TO REPRODUCE: Written permission to republish any parts of works published in *CHEST* must be obtained in writing prior to publication. Permission for republication of whole articles must be arranged by writing for permission at the Editorial Office address and through payment of any required royalty if permission is granted.

PHOTOCOPYING: *CHEST* is registered with the Copyright Clearance Center (CCC). Those wishing to photocopy parts of *CHEST* beyond that permitted by "Fair Usage" under US Copyright Law must report such usage to CCC. A fee of \$3.00 per article copy is payable on behalf of *CHEST* to CCC at 222 Rosewood Drive, Danvers MA 01923, or call (978) 750-8400.

For not-for-profit or educational classroom use that is not related to advertising and promotional purposes by a for-profit organization, a fee of \$0.25 per page per copy should be paid to the Academic Permissions Service at the above address for CCC on behalf of *CHEST*.

REPRINTS: For orders of 100 reprints or more, contact Customer Service, Poole Press, Inc., at (800) 798-9111 or poolepress@aol.com.